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1. Introduction 
 
1.1 Kidney transplantation – graft loss and patient survival 
Kidney transplantation is the current treatment of choice for patients with end-stage renal 
disease. Over the last 10 years, the number of kidney transplantations in the US has increased 
by 27% from 12 633 transplants in 1999 to 16 067 transplants in 2008 [1-2]. Although the 
number of transplantations per year may seem impressive, there is still a big difference 
between the number of donors and the number of patients on the waiting list (Figure 1.1) [2]. 
  
  
Figure 1.1 Number of kidney transplants between 1999 and 2008, and the number of 
patients on the waiting list. Tx, transplantation;  [Source:[2]; with permission] 
  
Improvement of the immunosuppressive therapy has resulted in a significant decrease in the 
incidence of acute rejection episodes after kidney transplantation and thus, in improving of 
the short term graft survival [3]. Basing on the US kidney transplantation report from the 
period between 1998 and 2007, we can observe that the one year graft survival increased from 
89% in 1998 to 91% in 2007 for deceased donors and from 95% in 1998 to 97% in 2007 for 
living donors [2]. Although the long-term allograft survival has also improved, the annual rate 
of graft loss remains relatively high. For kidney transplants performed before 2007, graft 
survival was best for recipients of living donor kidneys, intermediate for non-expanded 
criteria donor and lowest for expanded criteria donor transplants. Patient survival followed 
the same pattern (Figure 1.2) [1-2, 4-5].  
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Figure 1.2 Patient and renal graft survival by donor type. Three months, one year (for 
transplantations during 2006-2007), 5-year (for transplantations during 2002-2007) and 10-
year (for transplantations during 1997-2007) follow-up time. ECD - expanded criteria donor. 
[Source:[2]; with permission] 
 
It is of importance to identify the risk factors, which influence the long-term graft survival, to 
improve immunosuppressive therapy and post transplant care.  
 
1.2 Allograft rejection 
Organs undergoing acute rejection are infiltrated by host leukocytes, which cause graft cell 
necrosis and vessel thrombosis. Clinically, the commonly used immunosuppressive agents 
prevent or reverse most acute rejection episodes [6]. However, acute rejection episodes, even 
when completely reversed, are important risk factors for the development of chronic allograft 
rejection [7-9]. The estimated half-life of the transplanted organ is much lower in patients 
who underwent acute rejection episodes (6.6 years) than those who did not (12.5 years) [10]. 
It has been shown that the type of acute rejection, its timing and the number of acute rejection 
episodes play an important role in future development of chronic rejection [10], however, the 
contribution of the severity of acute rejection episodes to chronic rejection remains unclear 
[11]. The occurrence of an acute rejection episode within the first three months after 
transplantation is very common. It can be diagnosed in over 83% of renal grafts and does not 
necessarily influence the long-term graft outcome [12]. Acute rejection episodes between the 
2nd and the 6th months after transplantation however, can be a risk factor for the development 
of histopathological lesions in the grafts [13]. Despite the use of immunosuppression and 
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correct transplant aftercare, more than 21% of patients experience more than one acute 
rejection episode during the first posttransplant year [12]. 
Chronic renal rejection is the principal cause of long-term graft failure, and occurs in 50% to 
80% of the patients who return to dialysis after transplantations [14]. It develops over months 
and leads to graft loss in a period of years. It is defined by chronic allograft vasculopathy 
(CAV), transplant glomerulopathy (TG), tubular atrophy (TA), and/or interstitial fibrosis (IF) 
[9, 15-21]. 
 
1.2.1 Chronic allograft vasculopathy (CAV)  
CAV is one of the causes of long-term dysfunction of the allograft. The process of 
development is well described and similar for the heart (the abbreviation CAV is also used for 
cardiac allograft vasculopathy or coronary allograft vasculopathy) and for the kidney [22-25]. 
CAV is characterised by progressive fibrointimal thickening of arteries, arterioles and 
glomerular tufts [20, 25-26] and can be observed in the allograft as early as one month after 
transplantation [27-28]. Thickening of the arterial wall is caused by infiltrating inflammatory 
cells (macrophages, lymphocytes), proliferating vascular smooth muscle cells  (VSMC) [22] 
and myofibroblast, which accumulate in the intima, as well as by duplication or breaking of 
the internal elastic membrane [25], and finally, endothelial cell (EC) proliferation [29]. It 
reduces the blood flow in the organ and contributes to TG and tubulointerstitial lesions, which 
result in late allograft damage and failure [30]. In the pathophysiology of CAV, both 
immunologic factors (acute rejection episodes, chronic inflammation, hypertension, etc.) and 
non-immunologic factors (age, sex of the donor, smoking, ischemia-reperfusion injury, etc.) 
play a role [23-24]. It has been proposed that damage and apoptosis of EC may initiate the 
fibrointimal changes characteristic for CAV [31]. During chronic renal rejection, T-cell and 
antibody dependent pathways play a role in destruction of the allograft cells [25]. The 
vascular EC layer is the first component challenged by the immune system of the recipient 
[25] (Figure 1.3).  
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Figure 1.3: Mechanisms triggering allograft vasculopathy. Allograft vasculopathy can be 
caused by both immunological and non-immunological factors. EC, endothelial cells; FGF, 
fibroblast growth factor; IL, interleukin; PDGF, platelet-derived growth factor; SMC, smooth 
muscle cell; TGF-, transforming growth factor- [Source: [24]; with permission]. 
 
Disruption of the EC monolayer results in attachment and adherence of platelets circulating in 
the blood stream. They release platelet-derived growth factor (PDGF), which causes VSMC 
migration and proliferation at the place of injury [32]. Next, leukocytes (mainly monocytes) 
are attracted. They secrete numerous cytokines and growth factors like vascular endothelial 
growth factor (VEGF), PDGF, basic fibroblast growth factor (bFGF), transforming growth 
factor-α and -β (TGF-α, TGF-β) or interleukin-1 (IL-1), which also promote VSMC 
proliferation and migration to the intima [29]. In normal arteries, the extracellular matrix 
(ECM) prevents VSMC from migration, however, after injury, the ECM undergoes changes 
to allow cell movement. Finally, proliferation of EC allows rebuilding the endothelial layer, 
which was damaged upon injury.  
It has been shown that the thickness of the arterial intima increases four months after 
transplantation, but no further changes were observed on follow-up biopsies one year after 
transplantation [33]. CAV significantly decreases the long term graft survival (41% vs. 82% 
in patients with chronic allograft nephropathy (CAN) but without vessel narrowing) [34]. 
 
1.2.2 Transplant glomerulopathy (TG)  
TG is another pathological condition of renal allografts associated with very poor allograft 
survival [15]. TG is rarely diagnosed during first 6 months after transplantation but the 
probability is increasing to 4% during the first year, and to over 20% after 5 years [19]. It is 
commonly observed in patients with ongoing acute rejection or with a history of acute 
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rejection episodes (54% of TG positive biopsies were obtained from patients with a history 
of acute rejection). TG can be easily observed by light and electron microscopy [15-16, 19, 
26]. The most characteristic lesion for TG is thickening or doubling of the glomerular 
basement membrane (GBM). It can be seen after Periodic acid-Schiff and/or silver staining 
of kidney sections [15]. Less specific changes (which can occur not only in TG) include 
partial or global sclerosis or enlargement of glomeruli, which is an effect of increased size of 
endothelial and mesanglial cells, infiltration of the glomeruli with mononuclear cells and loss 
of continuity in GBM [9, 26]. Early TG does not necessary affect all glomeruli in the kidney 
[15]. Clinically, TG is characterised by proteinuria, progressive reduction of graft function 
and hypertension [35]. A reduced glomerular filtration rate between 6 and 12 months is 
associated with the development of chronic rejection after 12 months [36]. 
 
1.2.3 Tubular atrophy (TA) and interstitial fibrosis (IF)  
IF and TA are common signs of progressive loss of graft function, especially when observed 
together with CAV and TG. Tubular epithelial cells and tubulointerstitial fibroblasts may be 
damaged during organ inflammation or injury [17, 37]. Together with patchy fibrosis of the 
interstitium and atrophy of the tubules, there is infiltration by lymphocytes and macrophages 
[18]. The basement membrane of the tubules is thickened and/or duplicated, and peritubular 
capillaries disappear. In atrophic tubules, intratubular mononuclear cells can be seen. 
Numerous risk factors have been correlated with the development of IF/TA during the first 
year after transplantation. They are similar to the risk factors connected with TG or CAV and 
include ischemia-reperfusion injury, donor age and previous episodes of acute rejection [18]. 
In kidney biopsies, tubulointerstitial changes were diagnosed already 6 weeks after 
transplantation in 5% of grafts, at three months in 11% [38],  at 4 to 6 months between 37 
and 40% [38-39], and at one year in approximately 50% of the grafts [40]. Clinically, IF/TA 
scoring is more commonly used than TG or CAV scoring. In small biopsy cores, there is 
frequently more tubulointerstitial space than glomeruli or arteries, which can be investigated 
[18]. It is also possible to quantify precisely the area of IF by histomorphometry [41]. 
 
1.3 Experimental models for chronic renal allograft rejection 
The most commonly used model to study chronic renal allograft rejection is transplantation 
in the Fischer 344 (F344) to Lewis (LEW) rat strain combination [42-43]. It was first 
described by White et al. in 1969 [44]. The F344 (RT1lvr) rat has a variant l haplotype that 
differs from LEW (RT1l) in the major histocompatibility complex class I E/C region but is 
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identical to LEW in the immunodominant RT1.A and RT1.B regions [45]. This model allows 
to analyse the progression of chronic rejection which is characterised by slow reduction of 
the functions of the organ [46]. The renal grafts survive over 60 weeks and develop typical 
histological changes comparable with CAN [44]. At 4 weeks after transplantation, 
mononuclear cell infiltration, thickening of the GBM and proliferation of the mesanglial cells 
are observed. At 12 weeks, the mononuclear infiltration of the vessel walls is increased along 
with progressive damage of the glomeruli (together with further thickening of the basement 
membrane). The tubular basement membrane is also thickened. At 28 weeks, there are clear 
sings of IF and CAV – with intimal hyperplasia and disruption of internal elastic lamina [44]. 
At present, this model is widely used. In most studies, the immunosuppressive drug –
cyclosporine – is administered to the animals for 10 days after transplantation [44].  
The F344 to LEW rat strain combination is also used in this study to investigate chronic 
rejection of renal allografts, however, no immunosuppression is given after transplantation. 
Renal allografts in LEW recipients develop all functional and histological symptoms of 
CAN, which are described for human renal grafts. It has already been shown that after 
transplantation in the F344 to LEW rat strain combination. Reversible acute rejection 
developes and mononuclear leukocytes accumulate in the blood vessels of renal allografts 
and the cell number peaks around day 9 post-transplantation [47].  
 
1.4 From acetylcholine (ACh) to CAV 
 
1.4.1 ACh in fatal acute rejection 
Previous studies in our laboratory focused on fatal acute rejection. Allogeneic 
transplantations were performed in fully allogeneic Dark Agouti (DA) to LEW rat strain 
combination and isogeneic transplantation in LEW to LEW rat strain combination. 
Numerous leukocytes accumulate in the lumen of the blood vessels of the allografts before 
irreversible destruction of the organ (between days 4 and 5) [47-48]. 14% of these cells are 
T-cells and over 70% are activated monocytes, which have proinflammatory properties [49-
50]. In renal isografts, the cell population consists of about 50% of mildly activated 
monocytes [49]. The presence of ACh and the enzymatic machinery for its synthesis (choline 
acetyltransferase (ChAT) and high affinity choline transporter (CHT1) has been shown 
before in blood lymphocytes of both rats and humans. They are considered as a major source 
of non-neuronal ACh in the blood [51-55]. Moreover, it has been shown that mononuclear 
monocytes, which accumulate in the graft vessels during fatal acute rejection are a source of 
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ACh [48]: ChAT and CHT1 mRNA and proteins are upregulated upon acute allograft 
rejection. Additionally, immunohistochemical analysis revealed that numerous intravascular 
monocytes are positive for ChAT and CHT1 proteins [48]. 
 
1.4.2 ACh in vascular remodelling 
The importance of CAV in the progression of chronic allograft rejection is known and well 
described (1.2). Moreover, there are hints that interactions of accumulated blood leukocytes 
in the vessels of the allograft with vascular endothelial cells play an important pathogenic 
role for the development of CAV [25, 49-50, 56-59]. Interestingly, EC, SMC and immune 
cells are among several non-neuronal cell types, which produce ACh [60], a factor involved 
in cell proliferation, differentiation and intercellular communication [60].  
 
1.4.3 ACh and nicotine – ligands for nicotinic ACh receptors 
Both EC and VSMC express nicotinic (nAChR) and muscarinic (mAChR) cholinergic 
receptors. Several studies have indicated the role of nAChRs in cell proliferation and 
angiogenesis, which suggests their involvement in the process of vascular remodelling [61-
63]. ACh is the physiological ligand for nAChRs, however, nicotine and NNK (nicotine-
derived nitrosamine ketone, a tobacco smoke component) are also high affinity agonists of 
the nAChRs [61]. 
nAChRs are ligand-gated ion channels, built from five subunits. The variety of the subunits 
(9 4 , and) allows formation of receptors with different functions and affinities to 
ligands [64]. The structure of all subunits is similar and includes an extracellular domain (N-
terminal), four transmembrane domains, one intracellular domain, and a small extracellular 
domain (C-terminal). ACh and other agonists bind to the N-terminus [65]. It has been 
demonstrated that the proliferative and angiogenic effects of nicotinic agonists are mediated 
by 7-nAChRs [63]. 
It is known that tobacco smoking is associated with many pathologies of the blood vessels, 
like peripheral vascular diseases, which result in a reduction in vascular density and 
decreased vessels diameter [66-67]. Nicotine is the major addictive and best known tobacco 
component. Although nicotine has not been shown to be carcinogenic by itself, several 
studies show that nicotine or nicotine derivatives (e.g. NNK) enhance proliferation of 
endothelial cells via α7-nAChRs and induction of growth factors [66, 68-72]. If nicotinic 
stimulation of endothelial cells results in pro- or antiinflammatory effects is still disputed. 
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Antiinflammatory effects were reported for stimulation of endothelial α7-nAChR [73-74]. In 
contrast, long-term treatment with nicotine results in arterial inflammation and 
atherosclerotic lesions. This is at least in part due to a direct induction of prothrombotic
tissue factor expression by endothelial cells [75] but also to indirect effects mediated by
dendritic cells and macrophages [76-77]. 
Nicotine enhances the expression of many important growth factors and mediators of 
angiogenesis. VEGF expression is induced by nicotine in cancer [66, 78-80]. This effect is 
mediated by nAChRs. Treatment with mecamylamine, an inhibitor of nAChR, reduces 
plasma levels of VEGF in animals with tumor [81]. Nicotine has been shown to increase the 
VEGF receptor 2 expression in EC from angiogenic vessels [66, 78-79, 82]. This effect can 
be inhibited by the nAChR antagonist,  hexamethonium [83]. bFGF, PDGF, TGF-factors 
which promote SMC proliferation, can also be up-regulated by nicotine [84-85]. Nicotine 
induces the secretion of prostacycline, which is connected with EC survival and migration. 
Prostacycline can also promote VEGF and FGF mediated angiogenesis [86-87]. Nicotine has 
been shown to  increase the release of endothelin from EC [88]. Under certain conditions, 
endothelin can work as  a proangiogenic factor [89-90]. Among other antagonists of nAChRs 
there are mecamylamine a non-selective antagonist, which has been shown to inhibit the 
endothelial network formation during in vitro studies on angiogenesis [84] and α-
bungarotoxin, an antagonist of  nAChRs, which has been shown to inhibit tube formation of 
endothelial cells in vitro [62]. 
 
1.4.4  ACh synthesis in non-neuronal cells 
ACh is synthesised from acetyl-CoA and choline with the help of ChAT (Figure 1.5). While 
acetyl-CoA is produced in mitochondria, choline has to be transported from extracellular 
space. It is the rate-limiting step of the synthesis, which depends on CHT1. In the absence of 
ChAT, an alternative enzyme - carnitine acetyltransferase (CarAT) - can be used to 
synthesise ACh. Storage and release of ACh is mediated in neurons by the vesicular ACh
transporter (VAChT), which is not an essential component of non-neuronal cholinergic cells. 
However, there is evidence of ACh release via polyspecific organic cation transporters 
(OCTs) 1, 2 and 3 [91-92]. After releasing, ACh is rapidly hydrolysed by 
acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) into choline and acetate [93-
94]. 
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Figure 1.4: ACh synthesis and recycling in non-neuronal cells. CHT1, high affinity 
choline transporter; ChAT, choline acetyltransferase; Acetyl-CoA, acetyl coenzyme A; A, 
acetate; Ch, choline; ACh, acetylcholine. 
 
1.4.4.1 Choline acetyltransferase (ChAT) gene and protein  
ChAT is a globular protein with apparent molecular weight of 68 kDa (68 kDa in human and 
pig neuronal tissue, 67 kDa in rat neuronal tissue) [95]. However, isoforms of ChAT with a 
different molecular mass can be produced due to the alternative splicing (82 kDa variant of 
neuronal ChAT in humans; 67, 54 and 13 kDa in Drosophila; 41 and 54 kDa in human 
airway epithelial cells) [96-99]. In some species, the molecular weight of ChAT is lower than 
the predicted one (calculated from amino acid sequence form cloned cDNA). The difference 
could be due to post-translational modifications [95]. In all species investigated, ChAT is a 
product of a single gene (which also encodes VAChT within the first intron). Although there 
is high similarity in coding regions of ChAT nucleotide sequences of human, rat, mouse and 
pig, there are differences in non-coding regions [100]. A variety of mRNA species has been 
identified in mouse (R1-R4, N1-N2, M) rat (R1-R2, N1-N2, M) and human (R2, N1-N2, M) 
(Figure 1.6) [100-102]. 
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Figure 1.5: Splicing patterns of different ChAT mRNA species [Source: [95]; with 
permission]. ChAT, choline acetyltransferase; (■), common coding region of ChAT;  (□), 
non-coding regions; ( ), possibly translated regions in human M-type only; R1-R4, N1-N2,
M, non-coding exons.   
 
ChAT in human nerve terminals exists in two forms – a soluble (80-90% of the enzyme 
activity) and a membrane-bound form (10-20%) [103-104]. Besides the central and the 
peripheral nervous system, ChAT expression has been found in numerous mammalian cells, 
like epithelial cells (airways, intestine, epidermis, stomach, kidney pelvis, urinary bladder), 
endothelial cells (veins, vessels) and in immune cells (lymphocytes, alveolar macrophages, 
granulocytes, monocytes), including 13 human leukemic cell lines [48, 53, 93, 105-107]. In 
B-cell lines, a weak activity of the enzyme was detected, but no ChAT mRNA was found 
[108].  
ChAT has a high specificity for choline, but is less specific for acetyl-CoA and shows equal 
affinity for propionyl-CoA and butyryl-CoA. Besides ACh, ChAT can synthesise 
propionylcholine and butyrylcholine [109]. The ACh content in lymphocytes has been shown 
to correlate with ChAT activity and after lymphocyte stimulation, the ChAT activity is 
increased [110]. Casein kinase II as well as protein kinase C can increase ChAT activity
[111]. Nerve growth factor has also been reported to increase ChAT activity, which increased 
ACh release [112].  
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1.4.4.2 Carnitine acetyltransferase (CarAT)  
CarAT also belongs to the family of choline/carnitine acetyltransferases. It is a mitochondrial 
enzyme, which participates in ACh synthesis in the peripheral nervous system. Although 
CarAT has been reported to be expressed in lymphocytes, its expression did not correlate with 
ACh synthesis [110], which suggested a minor role in the process. In contrast, Lips et al. 
[113] has shown that in the absence of ChAT mRNA in human urothelium, CarAT is the 
main enzyme responsible for ACh synthesis. CarAT has also been detected in some human 
leukemic cell lines together with ChAT. The enzyme activity varies between cell lines, but 
without any correlation with ACh synthesis [107]. 
1.4.4.3 High affinity choline transporter (CHT1) and choline transport 
Choline transport is one of the crucial processes for the function of all cells. Besides being a 
key element for ACh synthesis, it is needed for the synthesis of membrane phospholipids and 
signaling lipids [114-115]. There are two essential choline transport systems inhibited by 
hemicholinium-3 (HC-3): low-affinity (sodium independent), and high-affinity (sodium and 
chloride dependent) [116]. The high affinity choline transport was reported primarily in 
cholinergic neurons and proved essential for the ACh synthesis [117]. The inhibition of high 
affinity choline uptake with HC-3 reduced the cholinergic function [118]. The genes for non-
neuronal CHT1 were cloned for the first time by Okuda et al. in 2000 [119] from C. elegans 
and rat and proved to have the same characteristics as CHT1 in cholinergic nerve endings. 
Human, mouse, Limulus and Torpedo CHT1 genes have been isolated thereafter [120-123]. 
Rat CHT1 gene has the highest homology to mouse CHT1 (98%) and human CHT1 (93%), 
and less to other investigated species (from 52-72%) [124]. The 580 amino acid protein is a 
member of sodium dependent glucose transporter family [120, 123-124]. Although its 
sequence has about 25% identity to other members of the transporter family, it shows no 
similarities to the known neurotransmitter transporters [121-122, 124]. Later on, CHT1 has 
been detected in several non-neuronal cells, where it has been localised in the membrane: 
epithelial cells of human and rat skin, rat trachea, brain, lung, arterial smooth muscle cells, 
fibroblasts [125-127], MOLT-3 human leukemic cell line [128], and in intravascular 
leukocytes isolated from rat renal iso- and allografts [48]. Moreover, MOLT-3 produce more 
ACh than other T-cell lines and express CHT1 on a higher level while ChAT activity remains 
similar in all cell lines [110]. This shows that high affinity choline uptake is essential for ACh 
synthesis in non-neuronal cells as well as in cholinergic neurons. In intravascular leukocytes 
from rat renal allografts, increased ACh levels correlate with higher CHT1 and ChAT 
expression [48].  
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1.4.5 ACh transport and release – vascular acetylcholine transporter (VAChT) and 
organic cation transporters (OCTs) 
In neuronal cells, VAChT is responsible for the transport of newly synthesised ACh into 
synaptic vesicles (the concentration of ACh in these vesicles can be 100-fold higher than in 
the cytoplasm) [107, 129-130]. The VAChT gene is localised within the first intron of ChAT 
gene and both proteins have been co-localised in cholinergic neurons [131]. Lips et al. [113] 
showed that among non-neuronal cells, VAChT is localised in rat secretory cells of bronchial 
epithelium. No VAChT expression was found in skin [132], T-cells [107] or rat ciliary 
epithelial cells [92]. OCTs however, have been reported to be involved in ACh release in 
respiratory epithelium (OCT1, OCT2, OCT3) [92, 113] and human placenta (OCT1 and 
OCT3 [91]). Furthermore, OCT1/2 double knockout mice have an increased epithelial ACh 
content [133]. The presence of OCTs has been investigated in a variety of human and rodent 
cells and tissues. Their distribution is summarised in following table (Table 1.1): 
 
 OCT1 OCT2 OCT3 
 h r h r h r 
small intestine + ++ + + + + 
liver  ++ ++ - ++ ++ + 
spleen + + + Ø - + 
trachea + + + + + + 
lung + + + + + + 
kidney + ++ ++ ++ + + 
skin + + + + + + 
blood vessels Ø + Ø - + + 
brain + + + + + + 
spinal cord Ø Ø Ø Ø Ø Ø 
epithelial cells + + + + + + 
neurons Ø Ø + + + + 
lymphocytes Ø Ø Ø Ø Ø Ø 
macrophages Ø Ø Ø Ø Ø Ø 
Table 1.1: Tissue distribution of OCTs. ++ very strong expression, + strong expression , - no expression, Ø 
expression has not been investigated. h, human; r, rodent [according to [134]].  
 
1.4.6 ACh degradation - acetylcholinesterase (AChE)/butyrylcholinesterase (BChE) 
Two families of cholinesterases (ChE) are present in vertebrates: AChE and BChE [135]. In 
addition to neuronal cells, their expression was detected in virtually all mammalian non-
neuronal cells [94, 136-138]. Within milliseconds after release, ACh is hydrolysed by AChE 
into choline and acetate [93-94]. Thus, the widespread action of ACh is prevented and 
restricted to the vicinity of cells, which are able to release this signaling molecule [93]. 
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1.4.7 AChE/BChE inhibitor – rivastigmine 
In his studies on the role of nicotine in pathological angiogenesis, Cooke et al. [139] showed 
that inhibition of AChE with neostigmine (and therefore increasing the availability of ACh) 
accelerates the migration of EC in vitro. The effect was similar to low dose VEGF, and 
suggested the involvement of both ACh and VEGF in angiogenesis [139]. In this study, 
another inhibitor – rivastigmine - has been used. Rivastigmine tartrate is a dual-specific, 
reversible inhibitor of both AChE and BChE [140], widely used in Alzheimer’s patients for 
treating dementia [141]. 
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2. Hypotheses 
Chronic allograft vasculopathy (CAV) is an important aspect of chronic allograft injury 
(CAI), which limits the long-term success of renal transplantation. The pathogenesis of CAV 
is ill-defined and no effective therapies exist. Acute rejection episodes are a major risk factor 
for CAV. Our laboratory recently demonstrated that leukocytes, which strongly accumulate in 
allograft blood vessels during fatal acute rejection, produce ACh, which has the potential to 
provoke vascular remodelling. Here, we test the hypotheses that 1) ACh is produced by 
intravascular graft leukocytes during the development of renal CAV and that 2) Endogenous 
ACh contributes to the pathogenesis of CAV. 
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3. Materials and methods 
 
3.1 Materials  
 
3.1.1 Reagents and consumables 
 
2-mercaptoethanol (ß-mercaptoethanol) (Sigma-Aldrich, Seelze; M-6250) 
3,3’-diaminobenzidine tetrahydrochloride (Sigma-Aldrich, Seelze; D5905) 
6 x loading dye solution (Fermentas, St. Leon-Rot) 
Acetic acid (glacial) 100% p.a. (Merck, Darmstadt; 1.00063.1011) 
Acetone p.a. (Merck, Darmstadt; 1.00014.1011) 
Agarose, Ultra PureTM (Invitrogen, Barcelona, Spain; 398611) 
Aluminum potassium sulfate (Merck, Darmstadt; 1042) 
Ampicilin (Ratiopharm, Ulm) 
Aniline Blue, diammonium salt (Sigma-Aldrich, Seelze; 415049) 
Aniline, ACS reagent 99.5% (Sigma-Aldrich, Seelze; 242284) 
Aqua ad injectabilia (B. Braun, Melsungen; 3450317/6874361) 
Aqua B. Braun (sterile water for irigation) (B. Braun, Melsungen; 75/12604052/0503) 
APS, ammonium persulfate  98% p.a. (Roth, Karlsruhe; 9592.3) 
Azokarmine G (Sigma-Aldrich, Seelze; A109-1) 
Brilliant Blue G, 90% (TLC) (Sigma-Aldrich, Seelze; B5133) 
BSA, albumin bovine fraction V (Serva, Heidelberg; 15903) 
Citric acid monohydrate p.a. (Merck, Darmstadt; 1.00244.0500) 
DNA ladder, GeneRuler™ 100 bp (Fermentas, St. Leon-Rot) 
Dulbecco’s PBS 1 x (Ca2+and Mg2+-free) (PAA Laboratories, Pasching, Austria; H15-002) 
EDTA, ethylenediaminetetraacetic acid (Sigma-Aldrich, Steinheim; E9884) 
EnVision® System-HRP labelled polymer anti-rabbit (Dako, Carpinteria, USA; K4003) 
EnVision® labelled polymer-AP mouse/rabbit (Dako, Carpinteria, USA; K4018) 
Ethanol p.a. (Sigma-Aldrich, Seelze; 322205) 
Ethidium bromide solution 1% (10 mg/ml) (Roth, Karlsruhe; 2218.2) 
Fast Blue BB Salt (Sigma-Aldrich, Steinheim; F3378) 
Fast Red TR Salt (Sigma-Aldrich, Steinheim; F6760) 
Filter paper, Whatman (GE Healthcare Ltd., Buckinghamshire, UK) 
Glycergel Mounting Medium (Dako, Carpinteria, USA; 10016653) 
Glycerol for electrophoresis, 99% (Sigma-Aldrich, Steinheim; G8773) 
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Glycine 99% p.a. (Roth, Karlsruhe; 3908.2) 
Goat-anti-rabbit immunoglobulins/HRP; polyclonal (Dako, Glostrup, Denmark; P0448) 
Haematoxylin (Merck, Darmstadt; 15938) 
HCl, hydrochloric acid 1 N (Merck, Darmstadt; 1.09057.1000) 
HCl,  hydrochloric acid 25% p.a. (Roth, Karlsruhe; 6331.1) 
Heparin ratiopharm 25 000 IE/5 ml (ratiopharm, Ulm) 
Hydrogen  peroxide, H2O2, 30% p.a. (Merck, Darmstadt; 1.07209.1000) 
IQTM SYBR Green Supermix (Bio-Rad, München; 170-8880) 
Isofluran (Forene, Abbott GmbH & Co. KG, Vienna) 
Isopropanol, 2-propanol p.a. (Sigma-Aldrich, Steinheim; 33539) 
KH2PO4, potassium dihydrogen phosphate p.a. (Merck, Darmstadt; 1.04873.0250) 
Levamisole hydrochloride (Sigma Chemical, St. Louis, USA; L-9756) 
Loading dye solution (6 x) (Fermentas, St. Leon-Rot) 
Lumi-Light Western Blotting Substrate (Roche Diagnostics, Mannheim; 12015200001) 
Methanol p.a. (Sigma-Aldrich, Steinheim; 32213) 
Methenamine silver plating kit (Merck, Darmstadt; 1.00820.0001) 
MgCl2, 25 mM (Promega, Madison, WI, USA; A351B 20733028) 
Micro BCA TM Protein Assay Kit (Thermo Sci., Rockford, USA; 23235) 
Milk powder (Blotting grade) (Roth, Karlsruhe; T145.3) 
M-MLV RT 5 x buffer (Promega, Madison, WI, USA; M531A 23713924) 
M-MLV RT, RNase H(-) Point Mutant (Promega, Madison, WI, USA; M368B 23031114)  
NaCl, sodium chloride 99% p.a. (Roth, Karlsruhe; 3957.1) 
NaCl, sodium chloride solution 0.9% (Diaco, Naila; 43-501/A) 
NaOH, sodium hydroxide solution 1 N (Merck, Darmstadt; 1.09137.1000) 
Naphtol AS-MX phosphate (Sigma-Aldrich, Steinheim; N4875) 
N,N-dimethylformamide, 99% (Sigma-Aldrich, Steinheim; D4551) 
Normal rat serum (NRS) (Harlan Winkelmann, Borchen)) 
Oligo(dT) 15 Primer (Promega, Madison, WI, USA; C110A 27017101) 
Orange G (Sigma-Aldrich, Steinheim; O3756) 
Orcein (Sigma-Aldrich, Steinheim; O7380) 
Ortho-phosphoric acid 85% (Sigma-Aldrich, Steinheim; 79617) 
Paraformaldehyde (polyoxymethylene), 95% (Sigma-Aldrich, Steinheim; 158127) 
PCR nucleotide mix (dNTP) (Promega, Madison, WI, USA; C114G 27917909) 
PercollTM (GE Healthcare Ltd., Buckinghamshire, UK; 17089101) 
Pertex (mounting medium) (Medite, Burgdorf; 177320) 
MATERIALS AND METHODS 
 17
Phosphotungstic acid (Sigma-Aldrich, Steinheim; P4006) 
Potassium chloride p.a. (Merck, Darmstadt; 1.04936.1000) 
Protease,  type XIV (Bacterial) (Sigma-Aldrich, Seelze; P5147) 
Protease inhibitor; Complete, mini protease inhibitor cocktail tablets (Roche Diagnostics 
GmbH, Mannheim; 11836153001) 
Protein marker, Precision Plus Protein TM dual color standards (Bio-Rad, CA, USA; 161-
0374) 
PVDF Transfer Membrane, Immobilon™ (Millipore; Roth, Karlsruhe) 
QIAquick Gel Extraction Kit (Qiagen, Hilden;  28704) 
Rabbit-anti-guinea pig immunoglobulins/HRP; polyclonal (Dako, Glostrup, Denmark; P0141) 
Rabbit-anti-mouse immunoglobulins/HRP; polyclonal (Dako, Glostrup, Denmark; P0161) 
Random Primers (Promega, Madison, WI, USA; C118A 26891012) 
Rivastigmine (Exelon, Novartis Pharma, Nürnberg) 
RNeasy® Mini Kit (Qiagen, Hilden; 74104) 
RNeasy® Lipid Tissue Mini Kit (Qiagen, Hilden; 74804) 
Rotiphorese® Gel 30 (aqueous 30% acrylamide and bisacrylamide stock solution at a ratio of 
37.5:1)  
RNase inhibitor, rRNasin® (Promega, Madison, WI, USA; N251A 27838805) 
Roti®-Histol (Roth, Karlsruhe; 6640.1) 
SDS (sodium dodecyl sulfate) ultra pure 99% (Roth, Karlsruhe; 2326.2) 
Silane, (3-aminopropyl) triethoxysilane, min 98% (Sigma-Aldrich, Seelze; A3648) 
Silicone solution in isopropanol (Serva, Heidelberg; 35130) 
Sodium azide 99%  (Merck, Darmstadt; 8223350100 ) 
Sodium dihydrogen phosphate dihydrate, extra pure (Merck, Darmstadt; 1.06345.1000 ) 
Sodium hydroxide solution, 1 N (NaOH) (Merck, Darmstadt; 1.09137.1000) 
Sodium hypochlorite solution 12% Cl (Roth, Karlsruhe; 9062.3) 
Sodium iodite ≥ 99.5% (Merck, Darmstadt; 106525) 
Sodium monohydrogen phosphate p.a. (Merck, Darmstadt; 1.06580.1000) 
Sodium pentobarbital (Narcoren®, 160 mg/ml, Merial, Hallbergmoos) 
Super-Signal® West Femto Kit (Thermo Sci., Rockford, IL, USA; 34094) 
TEMED 99% p.a., Elektrophorese (Roth, Karlsruhe; 2367.3) 
Trichlormethan/Chloroform, Rotipuran99,9% (Roth, Karlsruhe; 2006638) 
Trizma® base, min 99.9% (Sigma-Aldrich, Steinheim; T1503) 
Tween® 20 (for synthesis) (Merck, Darmstadt; 8.22184.0500) 
X-Ray developer concentrate (Adefo-Chemie GmbH, Dietzenbach; 00009) 
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X-ray film, high performance chemiluminescence film, Amersham HyperfilmTM ECL (GE 
Healthcare Ltd., Buckinghamshire, UK) 
X-Ray fixer concentrate (Adefo-Chemie GmbH, Dietzenbach; 00062) 
Xylene extra pure (Merck, Darmstadt; 1.08685.2500) 
 
3.1.2 Equipment 
 
AlphaEase FC software 3.3.0 (Alpha Innotech Corporation, San Leandro, USA) 
Balance, MXX-123 (Denver Instruments, NY, USA) 
Block heater (Peqlab Biotechnologies GmbH, Erlangen) 
Centrifuge, Micro 200R (Hettich Zentrifugen, Tuttlingen) 
Digital camera CC12 (Soft imaging system GmbH, Münster) 
Digital gel documentation system (Biozym, Hessisch Oldendorf) 
iCycler iQ, real-time PCR system (Bio-Rad Laboratories Inc., München) 
Microplate reader, FLUOstar OPTIMA (BMG Labtech, Offenburg) 
Microscope, BX511F (Olympus, Japan) 
Microtome, cool-cut HM355S (Micron GmbH, Walldorf) 
Mixer Mill, MM301 (Retsch GmbH & Co. KG, Haan) 
NanoDrop 1000 (Thermo Scientific, Schwerte) 
pH Meter, UB-10 (Denver Instruments, NY, USA) 
Temperature Cycling System, PCR Sprint (Hybaid Ltd., Ashford Middlesex, UK)  
Thermal Cycler, G-Storm GS482 (AlphaMetrix Biotech, Rödermark) 
Water bath, 3042 (Köttermann, Uetze/Hänigsen) 
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3.1.3 Buffers and solutions 
 
Acetic acid/alcohol 
100 ml 96% ethanol and 1 ml acetic acid (glacial) were mixed.  
 
Acidic Azocarmine G stain 
0.1 g Azocarmine G was dissolved in 100 ml aqua B. Braun. This solution was heated up, 
shortly boiled and after cooling, filtered through filter papers (Whatman). As a last step, 1 ml 
of acetic acid (glacial) was added.  
 
Acidic Orcein stain 
1 g Orcein was dissolved in 100 ml of 70% ethanol. After mixing, 1 ml of 25% HCl was 
added. This solution was prepared directly before use.                                                                                       
 
Alkaline phosphatase substrate solution 
1 mg Fast Blue BB Salt/Fast Red TR Salt was dissolved in 1 ml naphtol AS-MX phosphate 
buffer with levamisole. Additionally, the Fast Blue solution was centrifuged before use.  
 
Ammonium persulfate (APS) solution 
200 mg APS were dissolved in 400 ml of deionised water (DI-water). Solution was prepared 
shortly before use.  
 
Aniline alcohol 
100 ml 90% ethanol was mixed with 0.1 ml of aniline.  
 
Aniline Blue-Orange G stain 
0.5 g Aniline Blue and 2 g Orange G were mixed in 100 ml DI-water. After dissolving, 8 ml 
acetic acid (glacial) were added. This solution and was heated up, boiled for short time and 
filtered through Whatman filter paper. 
 
BSA solution (protein standard) 
50 mg of BSA was dissolved in 1 ml sample buffer I (2 x), heated for 5 min at 95°C and 
centrifuged for 5 min with 855 g. Afterwards, aliquots were prepared and stored at –20°C.   
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Citrate buffer (10 mM) 
9.45 g citric acid monohydrate was dissolved in 4.39 l DI-water. pH was adjusted to 6.0 with 
1 N NaOH (~112.8 ml) and DI-water was added to final volume of 5 l.  
 
The Coomassie Blue destain  
Following reagents were mixed: 
 350 ml methanol 
 24.5 ml acetic acid (glacial) 
 325.5 ml DI-water 
 
The Coomassie Blue stain 
Following compounds were mixed: 
 200 ml Coomassie Blue destain (see above) 
 50 mg Brilliant Blue G 
 
Hemalum stain 
1 g haematoxylin, 0.2 g sodium iodite and 50 g aluminum potassium sulfate were dissolved in 
1 l DI-water, and left for 24 h. Next, 50 g chloral hydrate and 1 g citric acid monohydrate 
were added. The solution was boiled for 5 min and filtrated afterwards. Before use, the 
solution was diluted 1:10 in DI-water. 
 
Loading gel buffer 
6.06 g of  Trizma® base was dissolved in 70 ml aqua B. Braun and the pH was set to 6.8 with 
1 N HCl. 4 ml of 10% SDS solution was added and the final buffer volume was adjusted with 
aqua B. Braun to 1 l. 
 
Naphtol AS-MX phosphate buffer with levamisole 
2 mg naphtol AS-MX phosphate were dissolved in 200 µl N,N-dimethylformamide. 9.8 ml of 
0.1 M Tris HCl (pH 8.2) and 4.8 mg of levamisole hydrochloride was added to the solution. 
 
Paraformaldehyde (PA) 8% 
50 ml DI-water was heated to 60°C. While stirring, 4 g PA and 75 µl 1 N NaOH were added. 
 
PBS 10 x (stock solution) 
The following compounds were dissolved in 900 ml DI-water: 
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 80 g NaCl  
 2 g  KCl  
 14.24 g Na2HPO4  
 2 g KH2PO4  
The pH was adjusted to 7.2 with 1 N HCl and the solution was filled up to a final volume of  
1 l. 
 
PBS 1 x (working solution) 
The stock solution (10 x PBS) was diluted 1:10 in DI-water. The pH was adjusted with 1 N 
HCl to 7.2. 
PBS/BSA/azide 
In 20 ml 1 x PBS were dissolved:  
 0.2 g BSA 
 0.02 g NaN3 
The pH (7.6) was tested with indicator strips. 
 
PBS/BSA/EDTA 
100 ml PBS 
27 mM EDTA 
0.1% BSA 
 
PercollTMsolution 
The following reagents were mixed: 
 8.8 ml aqua B. Braun  
 2.8 ml 1.5 M NaCl 
 16.4 ml PercollTM 
 60 µl 1 N HCl 
 
Peroxidase substrate (DAB) solution  
1 tablet 3,3’-diaminobenzidine tetrahydrochloride (DAB) was dissolved in 20 ml TBS. One 
ml aliquots of this stock solution were prepared and stored at –20°C.  
Shortly before using, 10 µl of 1.2% hydrogen peroxide were added to 1 ml DAB stock 
solution.  
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Protease solution 
This solution was prepared directly before using. One mg of protease powder was dissolved 
in 2 ml Tris-buffered saline (TBS). 
 
Running buffer  
The following compounds were dissolved in 900 ml DI-water: 
 6.08 g Trizma® base 
 28.84 g glycine 
 10 ml 10% SDS solution 
The final volume was adjusted to 1 l with DI-water. 
 
Sample buffer I (SB I) (2 x)  
The following reagents were mixed: 
 1.25 ml 1M Tris-HCl buffer 
 4.6 ml 10% SDS solution 
 4.15 ml DI-water 
 1 protease inhibitor tablet 
 
Sample buffer II (SB II) (2 x) 
The following reagents were mixed: 
 1.25 ml 1M Tris-HCl buffer 
 4.6 ml 10% SDS solution 
 1.6 ml 2-mercaptoethanol 
 2.55 ml glycerol 
 1 protease inhibitor tablet 
 
SDS stock solution (10%) 
10 g SDS were dissolved in 100 ml DI-water. 
 
Separating gel buffer 
18.16 g  Trizma® base were dissolved in 70 ml aqua B. Braun and the pH was set to 8.8 with 
1 N HCl. 4 ml 10% SDS solution were added and the final buffer volume was adjusted with 
aqua B. Braun to 100 ml.  
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Sørensen's phosphate buffer (2 x) 
The following compounds were dissolved in 500 ml DI-water: 
 3.08 g NaH2PO4 
 14.3 g Na2HPO4 
  
TBS 1 x (working solution) 
The following compounds were dissolved in 900 ml DI-water: 
6.05 Trizma® base  
9 g  NaCl  
The pH was adjusted to 7.6 with 5% HCl. The final volume was adjusted to 1l with DI-water. 
 
Transfer buffer 
Following reagents were mixed: 
 1.6 l DI-water 
 6 g Trizma® base 
 28.67 g glycine 
 10 ml 10% SDS solution 
 400 ml methanol 
 
Tris-acetate-EDTA (TAE) 50 x (stock solution) 
The following compounds were dissolved in 900 ml DI-water: 
242 g Trizma® base  
 57.1 ml glacial acetic acid  
 18.6 g EDTA.  
Final volume was adjusted to 1 l with DI-water.  
 
TAE 1 x (working solution) 
The stock solution (50 x TAE) was diluted 1:50 in dH2O. 
 
Tris-HCl buffer (0.1 M) 
12.1 g Trizma® base were dissolved in 800 ml DI-water. The pH was adjusted to 8.2 with 1 N 
HCl. The volume was adjusted with DI-water to 1 l.  
 
 
 
MATERIALS AND METHODS 
 24
3.2 Methods 
 
3.2.1 Transplantations 
All animal experiments were performed by V. Grau and K. Petri.  
 
3.2.1.1 Experimental animals 
Male Lewis (LEW(RT11)) and Fischer 344 (F344 (RT1lvl)), specified pathogen-free rats 
were provided by Harlan Winkelmann (Borchen, Germany) or Elevage Janvier (Le Genest, 
Saint Isle, France). Animal care and animal experiments were performed following the 
current version of the German Law on the Protection of Animals as well as the National 
Institutes of Health (NIH) principles of laboratory animal care. 
Transplantations were performed in LEW recipients at the age of about 2 months, weighting 
250-300 g. LEW rats were used as recipients and as donors for isografts. F344 rats were used 
as donors for allogeneic transplantations.  
 
3.2.1.2 Renal transplantation and treatment with rivastigmine 
Kidneys were transplanted orthotopically to totally nephrectomised recipients, according to 
the technique described by Fabre et al. [142] except that the ureter was anastomosed end-to-
end. Before surgery, donor (LEW or F344) and recipient (LEW) rats were anaesthetised with 
isofluran inhalation followed by 60 mg/kg sodium pentobarbital i.p. Additionally, donor rats 
obtained an injection of 1000 IU heparin per kg body weight. During surgery, rats were 
placed on a warming pad to keep their body temperature constant. Warm ischemic time was 
below 30 min. Recipient rats received a single dose of 30 µg ampicilin i.p. (Ratiopharm, Ulm, 
Germany). Isografts and allografts recipients were sacrificed at days 9, 42 and 6 months after 
transplantation, by an overdose of isofluran. 
A group of allograft recipients, which were investigated for a period of 6 months, were orally 
treated with 0.75 mg/kg body weight rivastigmine mixed with 100 µl apple juice. Placebo was 
100 µl apple juice mixed with 100 µl water. Animals were treated twice daily, from the 21st 
day after transplantation up to half a year after transplantation. After this time, rats were 
sacrificed by an overdose of isofluran. Graft recipients, which did not survive until day 4 after 
transplantation, were excluded from the experiment.   
 
3.2.1.3 Renal function 
Rats were weighted and placed in metabolic cages for urine collection. After 24 h, the volume 
of urine was measured as well as blood samples were obtained. Plasma creatinine and urea 
MATERIALS AND METHODS 
 25
concentration, as well as urine protein, creatinine, and urea were measured by the Laboratory 
of Clinical Chemistry, University Hospital Giessen and Marburg, Germany.  
 
3.2.1.4 Perfusion of the renal vasculature 
Leukocytes were isolated from the renal vasculature as described previously [49]. On days 9 
and 42 post-transplantation, graft recipients were anaesthetised and heparinised and the 
kidneys were perfused with cold PBS containing EDTA and 0.1% BSA via the Aorta. 100 ml 
of perfusate were collected on ice via the Vena cava.  
 
3.2.1.5 Purification of leukocytes 
Perfusates were centrifuged for 10 min at 4°C (500 g). After removing the supernatant, cells 
were resuspended in 10 ml PBS/BSA/EDTA and counted. For density gradient centrifugation, 
this cell suspension was filled up to 50 ml with PBS. Each 25 ml of the suspension was 
transferred on PercollTM (1.082 g/l) solution (two conical tubes, 14 ml each) and centrifuged 
for 30 min at 4°C (500 g). After centrifugation, about 20 ml of the fluid above the cell layer 
(interphase) could be removed. Afterwards, 1 ml of the interphase was collected. Interphases 
from both tubes were pooled, suspended in 50 ml PBS and centrifuged for 15 min at  4°C 
(500 g). After centrifugation, the supernatant was completely removed and pellet resuspended 
in PBS/0.1% BSA. Cells were counted, and aliquots of 5 x 106 cells were frozen in liquid 
nitrogen.  
 
3.2.1.6 Organ fixation and embedding 
Kidneys were cut in transversal slices of about 3 mm thickness. Specimens were fixed by 
immersion for 24 h in freshly dissolved 4% PA in 1 x Sørensen's phosphate buffer, followed 
by 24 h of washing in 1 x Sørensen's phosphate buffer at 4°C. On the 3rd day, pieces of the 
organ were immersed in 50% isopropanol for 30 min, and 3 x in 70% isopropanol for 2 h 
each. Next steps of embedding included placing the material once in 96% isopropanol and 
twice in 100% isopropanol for 1 h, each at RT. After dehydration, the material was incubated 
for 1 h in RT in the following solutions: 
 25% Roti®-Histol, 75% isopropanol 
 50% Roti®-Histol, 50% isopropanol 
 75% Roti®-Histol, 25% isopropanol 
 100% Roti®-Histol 
Later on, each piece was immersed in liquid paraffin heated to 60°C, which was replaced after 
2 h. The material was incubated in paraffin at 60°C over night.  
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3.2.2 Histology and immunohistochemistry 
 
3.2.2.1 Silanising glass slides 
Before using, glass slides were silanised according to the protocol indicated below, to prevent 
detachment of paraffin sections: 
 incubation in 5% HCl over night 
 washing in DI-water for 5 min 
 placing in isopropanol for 5 min 
 drying for 1 h at RT   
 immersing for 5 min in 2% silanes in acetone 
 immersing 2 x 5 min in 2% silanes in DI-water 
 washing in DI-water for 5 min 
 drying at ~100°C for 1 h 
 
3.2.2.2 Preparation of sections, dewaxing and rehydration 
7 µm sections were cut from the paraffin embedded material. 2 sections were placed on each 
silanised slide. All slides were first placed on slide warmer for about 30 min (38°C) to dry and 
then at ~100°C over night for better attachment of a section to the slide.   
Before starting with the immunohistochemistry staining protocol, embedded material was 
dewaxed and rehydrated according to the protocol indicated below: 
 3 x 10 min xylene 
 2 x 3 min 100% isopropanol 
 3 min 80% isopropanol 
 3 min 70% isopropanol 
 3 min 50% isopropanol 
 3 min DI-water 
 
3.2.2.3 Histology  
 
3.2.2.3.1 Taenzer-Unna acidic Orcein-staining 
To visualise arterial elastic membranes (internal and external elastic lamina), Orcein staining 
was performed. After dewaxing and rehydration, sections were immersed in freshly prepared 
acidic Orcein solution (3.1.3) for 30 min at RT. To wash out the stain, slides were rinsed with 
DI-water and placed in 100% isopropanol for 5 min to remove background staining, and thus 
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enhance the visibility of the stained elastic fibres. After 3 x 10 min in xylene, slides were 
mounted with Pertex. 
 
3.2.2.3.2 Heidenhein AZAN staining 
AZAN staining is a complex histochemical procedure which includes Azocarmine G and 
Aniline Blue to stain nuclei and erythrocytes red, muscle orange, and collagen in dark blue. 
After dewaxing and rehydration, sections were treated according to the following protocol: 
 immersion in aniline alcohol (3.1.3) for 1 min in RT  
 staining in pre-warmed acidic Azocarmine G stain (3.1.3) at 56°C for 15 min 
 washing with DI-water 
 aniline alcohol for 1 min (removing background staining) 
  acetic acid/alcohol (3.1.3) for 1 min  
  washing with DI-water 
 2 h at RT in 5% phosphotungstic acid 
 washing with DI-water 
 Aniline Blue-Orange G stain for 2 h at RT 
 washing with DI-water 
 96% ethanol for ~1 min (removing background staining) 
 3 x 10 min xylene 
 mounting with Pertex 
 
3.2.2.3.3 Gomori's methenamine silver staining 
To visualise GBM and mesanglial matrix on renal sections, Gomori’s methenamine silver 
staining was performed with the help of Methenamine silver plating kit (Merck), according to 
the manual provided by the manufacturer.  
 
3.2.2.4 Immunohistochemistry 
 
3.2.2.4.1 Single-staining  
For the detection of antigens in this study, a two step immunohistochemical staining 
technique was used. First, primary antibodies were applied to the section. Bound primary 
antibodies were detected using the rabbit EnVision® System (-HRP/-AP) according to the 
manufacturer’s recommendation. 
The following antibodies were used:  
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Antigen Host species Dilution Incubation 
condition 
CHT1[*], synthetic peptide, 
aa29-40 of rat sequence  
rabbit 1:8000 over night, 4°C 
ChAT[*], synthetic peptide,  
aa 282-295 of rat ‘common ChAT’ sequence  
rabbit 1:6000 over night, 4°C 
CD68-like, ED1 [Abcam, Cambidge, UK] mouse 1:500 2 h, RT 
Tab. 3.1 Antibodies and conditions needed for immunohistochemical staining. CHT1, 
high affinity choline transporter; ChAT, choline acetyltransferase; RT, room temperature; [*] 
Thanks to the generosity of Prof. W. Kummer from Institute of Anatomy and Cell Biology; 
JLU Giessen.  
 
After dewaxing and rehydrating (3.2.2.2), sections were rinsed for 3 min in TBS. Afterwards, 
sections were treated with 50 µl protease solution (3.1.3) for 15 min at RT, followed by 3 x 
washing with PBS. Endogenous peroxidase activity was inactivated by immersing the slides 
in 1% H2O2 in PBS for 30 min (6.6 ml 30% H2O2 added to 196.4 ml PBS). After washing in 
PBS (3 x 2 min), the sections were incubated for 30 min in 50 µl PBS/BSA/azide solution 
(3.1.3) to reduce unspecific antibody bindig.  
For each section, 50 µl of antibody diluted in PBS/BSA/azide solution were used. For 
antibody titers, time and temperature of incubation see Tab. 3.1. On control sections, the 
primary antibody was omitted. After incubation, unbound antibodies were removed by rinsing  
the sections with PBS (3 x). Bound primary antibodies were detected using 40 µl EnVision® 
System. Heat inactivated normal rat serum (NRS) was added to the EnVision® solution at a 
concentration of 5% to block antibodies cross-reacting with rat immunoglobulins. After 30 
min incubation at RT, unbound polymer  was washed away from sections by rinsing them 3 x 
with TBS (for HRP labelled polymer) or 0.1 M Tris HCl buffer (for AP labelled polymer).  
As a substrate for peroxidase, 100 µl of DAB solution (3.1.3) was used for each section. After 
10 min incubation at RT, a brown end product was visible. DAB solution was washed away 
by rising the sections 3 x with PBS (to detoxify DAB all solution, wastes,  tips, and cups used 
for storing DAB were washed with chloride hydrate before disposing). Selected sections were 
slightly counterstained with hemalum (dilution 1:10 in dH2O for 90 s).  
The brown end product of DAB reaction is insoluble in organic solvents, therefore all slides 
were dehydrated in isopropanol (3 min in each: 50%, 70%, 80%, 2 x 100%), cleared 2 x in 
xylene and mounted with Pertex.  
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To visualise bound AP, two different substrate solutions were used: Fast Blue (blue product) 
or Fast Red (bright red product) (3.1.3). Each section was covered with 100 µl of  substrate 
solution and placed in the dark for 20 min at RT. After incubation, slides were rinsed 3 x with 
PBS and mounted directly with warmed to 42°C Glycergel (aqueous mounting medium, as 
both end products are soluble in alcohol).  
 
3.2.2.4.2 Peptide competition assay (PCA) 
PCA experiments were performed to confirm the specificity of the immunohistochemical 
staining of polyclonal antibodies (CHT1 and ChAT). 100-200 µg of the peptide used to 
produce antibody were added to each ml of the dilution of the primary antibody and pre-
incubated for 1 h at RT before application to the sections. During this time, a positive control 
dilution of antibodies (without peptide) was stored at RT.  
 
3.2.2.4.3 Double-staining  
To verify that cells, which express CHT1 and ChAT are intravascular monocytes, double-
staining experiments with mouse monoclonal antibody (mAb) ED1 to a CD68–like protein 
were performed. The CD68-like antigen is expressed by the majority of macrophages, 
predominantly on the lysosomal membrane. First, primary antibodies (CHT1 or ChAT) were 
visualised with anti mouse/rabbit EnVision® AP (containing 5% NRS) and Fast Blue as 
chromogen (3.2.2.4.1). After rinsing with PBS, bound primary antibodies and EnVision®were 
detached from the sections by cooking for 15 min in a steamer in citrate buffer (3.1.3). After 
cooling down, the slides were washed in PBS 3 x 2 min, blocked once more with 
PBS/BSA/azide for 30 min and incubated for 2 h at RT with mAb ED1 diluted 1:500 in 
blocking solution. For antibody detection, anti mouse/rabbit EnVision® AP (+ 5% NRS) with 
Fast Red as chromogen were used. Three kinds of  controls were prepared: 
 omitting primary antibodies in both steps 
 omitting anti-CHT1 or anti-ChAT antisera 
 omitting mAb ED1 
Slides were mounted as described in 3.2.2.4.1. 
 
3.2.3 Protein biochemistry 
 
3.2.3.1 Protein assay and sample preparation 
Prior to electrophoresis, the total protein content was measured with the Micro BCATM 
protein assay kit. For the protein assay, intravascular leukocytes isolated by renal perfusion 
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(3.2.1.5) were solubilised in SB I. Later on, the sample was heated for 5 min to 95°C and then 
centrifuged for 5 min with 855 g. From that solution, 10 µl were taken to estimate the protein 
content. After measuring the protein content, a suitable amount of SB I and II were added to 
the sample. Samples were aliquoted and stored at –20°C.  
 
3.2.3.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The following compounds were used to prepare separating gel: 
 1.83 ml dH2O 
 1.08 ml separating gel buffer (3.1.3) 
 1.46 ml acrylamide solution (Rotiphorese® Gel 30) 
 7.7 µl APS solution (3.1.3) 
 3 µl TEMED 
The gel was poured in a gel caster. Next, a thin layer of isopropanol was added. Gel was left 
to polymerise in a humid chamber at 4°C over night. On the next day, the loading gel was 
prepared from following compounds:  
 1.35 ml dH2O 
 790 µl loading gel buffer (3.1.3) 
 652 µl acrylamide solution (Rotiphorese® Gel 30) 
 5.6 µl APS solution (3.1.3) 
 2.25 µl TEMED 
After pouring the loading gel, a comb was placed on the top to create wells. The gel was left 
to polymerise at RT for 0.5 - 1 h. After polymerization, the comb was removed, wells were 
rinsed with running buffer (3.1.3) and the electrophoresis chamber was filled with running 
buffer. Directly before electrophoresis, the samples (3.2.3.1) were heated for 5 min to 95°C 
and centrifuged for 5 min at 1920 g. Ten µl of each sample (which corresponds to 8 µg 
protein) were pipetted in a well. To estimate the size of the separated proteins, 10 µl of a 
prestained protein marker (10-250 kDa) were loaded. 
Electrophoresis condidtions: 
 10 min at 230 mA, 80 V 
 75 min at 230 mA, 120 V 
 
3.2.3.3 Transfer 
After separation on the gel, proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane to enable antigen detection. Before transfer, the gel was equilibrated in transfer 
buffer (3.1.3) for 5 min A PVDF membrane cut to the size of the gel was first soaked in 
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methanol for 1 min followed by 5 min in transfer buffer. Gel and membrane covered with 
filter paper were placed in a chamber filled with transfer buffer in the way that proteins from 
gel could migrate onto the membrane. After 90 min of transfer at 90 mA and 230 V, the 
membrane was taken out and air-dried at RT. The effectiveness of the transfer was checked 
by staining the gel with Coomasie blue stain.  
 
3.2.3.4 Blocking and detection of antigens 
The air-dried membrane was soaked in methanol for 1 min, followed by 5 min in PBS. In 
order to block non-specific protein binding sides, the membrane was placed in 5% milk 
powder (MP) in PBS for 1 h at RT. The membrane was incubated (under gentle agitation) 
with primary antibody diluted in 5% MP in PBS at 4°C over night. The dilution varied 
between different antibodies (see Tab. 3.2). 
After incubation over night, the membrane was rinsed 4 x 7 min with PBS + 0.1% Tween® 
(TPBS), followed by incubation with an appropiate HRP-labelled secondary antibody (Tab. 
3.2). In next step, the membrane was rinsed for 3 x 10 min in TPBS and additional 10 min in 
PBS. The membrane was covered with Lumi-Light Western blotting substrate for 5 min and 
the signal was detected using a X-ray film.  
 
Antigen Host species Dilution Secondary antibody Secondary antibody 
dilution & condiditons
CHT1 [*] 
 
Guinea pig 1/1500  Rabbit-anti-guinea pig 
Ig (HRP)  
1/5000 in 2.5% MP; 90 
min at RT 
ChAT [*] Rabbit  1/3000  Goat-anti-rabbit Ig 
(HRP)  
1/5000 in 2% MP; 60 
min at RT 
GAPDH [Abcam, 
Cambidge, UK] 
Mouse  1/20000  Rabbit-anti-mouse Ig 
(HRP)  
1/5000 in 2.5% MP; 90 
min at RT 
Tab. 3.2 Primary antibodies: characteristics and conditions for detection. CHT1, high 
affinity choline transporter; ChAT, choline acetyltransferase; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; Ig, immunoglobulin; HRP, horseradish peroxidase; MP, milk 
powder; RT, room temperature; [*] Thanks to the generosity of Prof. W. Kummer from 
Institute of Anatomy and Cell Biology; JLU Giessen. 
 
3.2.3.5 Densitometrical evaluation and statistics 
After scanning the blots, the bands were analysed by densitometry with the help of 
AlphaEaseFC software. Basing on the results, box plots and statistical analyses were made 
using the IBM SPSS Statistics 18 program.  
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3.2.4 Detection of mRNA  
 
3.2.4.1 RNA isolation  
RNA was isolated from intravascular mononuclear leukocytes from control kidneys, isografts 
and allografts as well as from renal tissue with the RNeasy® Mini Kit. As a positive control, 
total RNA was isolated from the trachea of healthy LEW rats with the RNeasy® Mini Kit and 
spinal cord with RNeasy® Lipid Tissue Mini Kit (Qiagen) according to the manual provided by 
the manufacturer. For each isolation, approximately 5 x 106 purified leukocytes or 30 mg 
tissue were used. The concentration of isolated RNA (given in µg/µl) was measured 
spectrophotometrically using NanoDrop 1000. Negative controls were performed by 
omitting the reverse transcription step and by adding H2O instead of the DNA template. 
 
3.2.4.2 Synthesis of complementary DNA (cDNA) 
After RNA isolation, reverse transcription was performed. To 0.5-1 µg of RNA, a mixture of 
random hexamers and oligo-dT primers was added at a concentration of 1 µg per 1 µg RNA. 
dH2O was added to a volume of 10 µl and the mixture was incubated for 5 min at 70°C and 5 
min at 4°C. Next, a mastermix was prepared: 
 5 µl  M-MLV RT 5 x buffer 
 1.5 µl PCR nucleotide mix (dNTP) 
 0.5 µl RNase inhibitor 
 0.5 µl M-MLV RT 
 7.5 µl  dH2O 
The reagents were mixed and combined with pre-incubated 10 µl of tRNA and primers. The 
final sample volume was 25 µl. The mixture was incubated for 10 min at 25°C, 1 h at 40°C 
and finally 15 min at 70°C.  The obtained cDNA was ready for direct use or could be stored at 
–20°C.  
 
3.2.4.3 Real-time quantitative PCR (qPCR) 
qPCR was performed on an iCycler iQTM real-time PCR system (Bio-Rad), and the results 
were analysed with the iCycler iQTM real-time detection system software. 
For preparing a master mix, the following reagents (for each sample) were used: 
 1 µl cDNA 
 10.5 µl dH2O 
 12.5 µl IQTM SYBR® Green Supermix 
 1 µl forward and reverse primers mixture (primer list – see Tab. 3.3) 
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After an initial polymerase activation and denaturation step at 95°C for 8.5 min, samples went 
through 40 amplification cycles: 95°C for 25, 60°C for 25, 72°C for 25 s, 5 min at 72°C. At 
the end, a melting curve was recorded (1 min at 95°C, 1 min at 55°C and then heating slowly 
at 0.5°C/s to 85°C). Samples were stored at 4°C before gel electrophoresis.  For each sample, 
a target gene and the housekeeping gene was investigated. After data calculation (Ct values), 
results were analysed statistically with IBM SPSS Statistics 18 software. 
Primer  Sequence (5’-3’) Accession number Product length 
(bp) 
PBGD fwd GGCGCAGCTACAGAGAAAGT 
NM_013168 115 
PBGD rev AGCCAGGATAATGGCACTGA 
CHT1 fwd CAAGACCAAGGAGGAAGCCAG 
NM_053521 150 
CHT1 rev GCAAACATGGAACTTGCTGA 
ChAT fwd TGGATGGTCCAGGCACAGGAGAGC 
NM_001170593.1 101 
ChAT rev TGGTCACACACCACACCGCAGGT 
OCT1 fwd TGGCCGTAAGCTCTGTCTCT 
NM_012697 151 
OCT1 rev TCAAGGTATAGCCGGACACC 
OCT2 fwd ATCACGCCTTTCCTCGTCTA 
NM_031584 161 
OCT2 rev CTGCATATTCTCGGCATCCT 
OCT3 fwd CAATGGGAAACACCTCTCGT 
NM_019230 153 
OCT3 rev ATACACCACGGCACTTGTGA 
VAChT fwd GCCACATCGTTCACTCTCTTG 
NM_031663 149 
VAChT rev CGGTTCATCAAGCAACACATC 
CarAT fwd AGAGTTTACCCAGCGTGAGG 
NM_001004085 147 
CarAT rev GGCCTTAAATCGACCAGACA 
Tab. 3.3 qPCR primer list. PBGD, porphobilinogen deaminase; CHT1, high affinity choline 
transporter; ChAT, choline acetyltransferase; OCT1, 2, 3, organic cation transporter 1, 2, 3; 
VAChT, vesicular acetylcholine transporter; CarAT, carnitine acetyltransferase; fwd, forward; 
rev, reverse 
 
3.2.4.3.1 Agarose gel electrophoresis 
To check the size and the purity of the amplified products, agarose gel electrophoresis was 
performed. 100 ml of (1.5-2%) agarose solution in TAE was heated. After cooling down to 
60°C, 3 µl of ethidium bromide solution were added. After cooling down, gel was placed in 
the running chamber filled with TAE solution. 8 µl of each sample mixed with 2 µl of a 6 x 
loading dye solution were pipetted per well. To estimate the size of the product, 8 µl of a 
DNA ladder were loaded. Electrophoresis condition: 25 min at 230 mA, 120 V. 
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3.2.4.3.2 DNA sequencing 
The DNA sequence of the amplified PCR-products was confirmed by DNA sequencing. 
Individual bands were cut from the agarose gel and the DNA was extracted with the 
QIAquick Gel Extraction Kit according to manufacturer's manual. Sequencing was performed 
by Eurofins MWG Operon (Ebersberg, Germany).  
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 4. Results 
 
4.1 Histopathology of kidneys transplanted in the F344 to LEW rat strain combination 
Experimental kidney transplantation in the F344 to LEW rat strain combination is an 
established model for human CAI [42-43]. Within 6 months after transplantation, allografts
develop CAV, which is characterised by intimal and medial hyperplasia (Figure 4.1, A-D). On 
day 9 after allogeneic transplantation, when reversible acute rejection peaks, arterial thickness 
(including Tunica (T.) media and T. intima) increases significantly (p≤0.05) compared with 
day 9 isografts. However, on day 42 after transplantation, there are no significant changes
between isografts and allografts, and the arterial thickness is comparable with the one of
healthy control kidneys. Six months after transplantation (on day 182), significant changes
(p≤0.05) in the thickness of arterial wall can be observed in allografts compared with
isografts. The lumen of the arteries in allografts on day 182 is dramatically reduced compared
with the arterial lumen in healthy control kidneys (Figure 4.1, D and C respectively). The
thickness of the renal arteries in all isograft groups remains similar to the thickness of the
arteries in healthy control kidneys (Figure 4.1, A). 
Additionally to the total thickness of arterial wall, the percentage of arteries exhibiting intimal
hyperplasia was estimated. Arteries in healthy control kidneys and arteries in day 9 isografts
and allografts, as well as day 42 and 182 isografts show virtually no signs of intimal 
hyperplasia. In day 42 allografts, however, there is a significant (p≤0.05) increase in the 
number of arteries exhibiting intimal changes compared with day 42 isografts. At this time
point, about 30% of renal allograft arteries exhibit intimal hyperplasia (Figure 4.1 B). Six 
months after transplantation (on day 182), the percentage of arteries with intimal hyperplasia
increases to 80% (p≤0.05) in allografts compared to about 20% in isografts (Figure 4.1 B and 
D).  
During chronic rejection, there is a significant (p≤0.05)  increase in the relative thickness of T. 
adventitia in all allograft groups, compared to isografts (Figure 4.2, A-C). The enlarged 
fibrotic adventitia surrounding allograft arteries (especially on day 9) is infiltrated by
leukocytes. The diameter of adventitia surrounding the arteries does not change significantly
after isogeneic transplantation (on days 9, 42 and 182), compared with healthy control
kidneys. In addition to vascular changes, glomerular damage (thickening of the GBM, partial
sclerosis and increase in the diameter of glomeruli), TA and IF are present in allografts but not 
in isografts or healthy control kidneys (Figure 4.3-4.4).  
RESULTS 
 36
 
Figure 4.1: Arterial thickness and percentage of arteries exhibiting intimal hyperplasia
during chronic renal rejection. Paraffin sections (7 µm) from the renal cortex of healthy
control kidneys (C), isografts (iso) and allografts (allo) on days 9 (9), 42 (42) and 182 (182)
after transplantation were stained with acidic Orcein. A. To measure the arterial thickness, the 
inner diameter of the artery surrounded by external elastic membrane (including media, intima
and lumen) was divided by the diameter of the vascular lumen. B. The percentage of arteries 
exhibiting intimal hyperplasia was estimated. C-D. Cross-sections of an artery from a healthy 
control kidney and a day 182 allograft, respectively. The box plots indicate median and
percentiles 0, 25, 75 and 100. 
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Figure 4.2: Thickness of T. adventitia after isogeneic (iso) and allogeneic (allo)
transplantation. A. The thickness of T. adventitia was measured on AZAN stained paraffin 
sections from the renal cortex of healthy control kidneys (C), isografts and allografts on days
9 (9), 42 (42) and 182 (182) after transplantation. From the outer arterial diameter (including 
the T. adventitia, media, intima and lumen) the inner arterial diameter (including media,
intima and lumen) was subtracted. This value was divided by the inner diameter. B-C. Azan 
stained cross-sections of the arteries from a healthy control kidney and a day 182 allograft 
respectively. The box plots indicate median and percentiles 0, 25, 75 and 100. 
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Figure 4.3: Histopathology of the renal cortex of isografts (iso) and allografts (allo) on days 
9 (9), 42 (42) and 182 (182) after transplantation. Paraffin sections (7 µm) were stained with
AZAN. Leukocyte infiltration, vascular remodelling, TA, glomerular damage, and general 
fibrosis are present in allogeneic but not in isogeneic kidneys. White arrows point to the 
adventitia surrounding arteries, black arrows point to glomeruli.  
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Figure 4.4: Glomerular damage during chronic renal rejection. PASM stained paraffin 
sections (7 µm) from the renal cortex of  A. a healthy control kidney and B-D. a day 182 
allograft. Thickening of the GBM, partial sclerosis and enlargement of glomeruli are visible in
the allograft (B-D) but not in the healthy control kidney (A).  
 
4.2 Number of intravascular graft leukocytes  
Numerous leukocytes are seen in the vasculature of day 9 allografts (Figure 4.5). These cells 
are less frequent on day 42 after transplantation but still increased in comparison to isografts.
The cell number remains increased in allografts until 6 months after transplantation.
Leukocytes accumulate in all parts of the vascular bed including arteries of the muscular type 
(Figure 4.5, black arrows). Some of the leukocytes adhere to vascular endothelia or form large
aggregates. To harvest leukocytes from graft blood vessels, renal transplants were intensively
perfused with cold PBS/BSA/EDTA and compared with the perfusate of healthy control
kidneys, which typically contain about 5 x106 leukocytes (Figure 4.6). In response to 
isogeneic kidney transplantation, the number of leukocytes recovered from graft blood vessels
increase by about twofold at both time points investigated (Figure 4.6). Reversible rejection, 
which peaks around day 9, results in a dramatic increase in intravascular cells to about 135
million cells. These results corroborate data published previously [47]. The cell number drops 
to about 30 million cells 42 days after transplantation, which is, however, still significantly
(p0.05) increased in comparison to day 42 isografts. Histopathological evaluation of the
grafts revealed that intensive perfusion mobilised virtually all leukocytes from the blood 
vessels and did not disrupt the integrity of blood vessels, including the vascular endothelium 
(Figure 4.7). 
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Figure 4.5: H&E staining of paraffin sections from the renal cortex of isografts and 
allografts on days 9, 42 and 182 after transplantation. Numerous leukocytes accumulate in 
the vascular bed of renal allografts on day 9 after transplantation. The number of intravascular
leukocytes in renal allografts remains elevated until 6 months after transplantation. White
arrows are pointing on leukocytes accumulating in the lumen of the veins and black arrows to 
the leukocytes present in the lumen of renal arteries.  
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Figure 4.6: Number of leukocytes in vascular perfusates of untreated LEW kidneys 
(control, C), isografts (iso) and allografts (allo) on day 9 (9) and day 42 (42) post-
transplantation. The box plot indicates median and percentiles 0, 25, 75 and 100; circles 
indicate data beyond 3 x standard deviation. 
 
 
 
Figure 4.7: Acidic Orcein staining of paraffin section from the renal cortex of a perfused 
kidney.  
 
4.3 Expression of CHT1, ChAT and CarAT mRNA by graft blood leukocytes 
The mRNA-expression of CHT1, ChAT and CarAT was analysed by RT-PCR in 
mononuclear leukocytes isolated from renal F344 to LEW allografts, isografts and healthy
control kidneys from LEW rats. Increased amounts of CHT1 mRNA were detected by real-
time RT-PCR in intravascular leukocytes from day 9 and day 42 allografts in comparison to
the respective isografts (p0.05) (Figure 4.8, A). In comparison to controls, isograft
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leukocytes expressed lower amounts of CHT1 mRNA (p0.05). ChAT mRNA was only 
detected in some samples, although in addition to real-time RT-PCR, conventional and nested 
RT-PCRs were applied (data not shown). In the spinal cord and in the trachea, which served
as positive controls, CHT1 and ChAT mRNA were detected. 
In addition to ChAT mRNA, the expression of CarAT mRNA by intravascular graft
leukocytes was investigated. There are no significant differences in the CarAT mRNA-
expression by intravascular leukocytes isolated from isografts and allografts on day 9
compared with leukocytes from healthy control kidneys. CarAT mRNA-expression in 
isografts on day 42 also remains on the control level. However, there is a significant (p0.05) 
increase in mRNA-expression in allografts on day 42 compared with isografts (Figure 4.8, B). 
After real-time RT-PCR, the melting curves of the products (CHT1 and CarAT) indicated
homogeneity and electrophoresis revealed a single band with the expected molecular weight 
(150 bp for CHT1 and 147 bp for CarAT). DNA sequencing confirmed the specificity of the 
PCR. In negative controls, no product was obtained. 
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Figure 4.8: Quantitative RT-PCR analyses of A. CHT1 and B. CarAT mRNA-expression 
in intravascular leukocytes isolated from healthy control kidneys (C), renal isografts (iso)
and allografts (allo) on days 9 (9) and 42 (42) after transplantation. Data are expressed as
arbitrary units, which are normalised to one unit in controls. The box plots indicate median 
and percentiles 0, 25, 75 and 100; the circle indicates a value beyond 3 x standard deviation. 
 
 
4.4 Expression of CHT1 and ChAT mRNA in renal tissue 
The mRNA-expression of CHT1 and ChAT was also analysed in the renal tissue. Tissue 
homogenates from F344 to LEW allografts, isografts and healthy control kidneys from LEW
rats were analysed by real-time RT-PCR. CHT1 mRNA is expressed in renal tissue at all time-
points investigated. Only in day 42 allograft kidneys, the expression of CHT1 mRNA is 
significantly (p0.05) lower compared with respective isografts (Figure 4.9, A). ChAT mRNA
is present in all isograft and allograft kidneys as well as in control renal tissue. There are no
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significant changes between the groups of interest (Figure 4.9, B). The melting curves of the 
products indicated homogeneity and electrophoresis revealed a single band with the expected
molecular weight corresponding to 150 bp for CHT1 and about 100 bp for ChAT. DNA
sequencing confirmed the specificity of the PCR. In negative controls, no product was
obtained. 
 
Figure 4.9: Quantitative RT-PCR analyses of A. CHT1 and B. ChAT mRNA-expression 
in renal tissue. Control kidneys (C), renal isografts (iso) and allografts (allo) on days 9 (9)
and 42 (42) after transplantation were investigated. Data are expressed as arbitrary units,
which are normalised to one unit in controls. The box plots indicate median and percentiles 0,
25, 75 and 100. 
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4.5 Expression of CHT1 and ChAT protein by graft blood leukocytes 
CHT1 and ChAT protein expression was investigated by immunoblotting of lysates of
mononuclear intravascular graft leukocytes using polyclonal antibodies against specific
peptides deduced from the amino acid sequence of CHT1 and ChAT proteins [48] (Figure 
4.10). Antibodies to CHT1 revealed one major band with an apparent molecular mass of 67
kDa in leukocytes from day 9 and day 42 allografts. In isografts, only a weak signal was
detected. Antibodies to ChAT stained one major band with a molecular mass of about 69 kDa
in leukocytes from day 9 and day 42 allografts. In isografts, the ChAT signal was weaker. 
Adding excess amounts of specific peptide to the primary antibody abolished CHT1 and
ChAT signals (Figure 4.10). Densitometrical analyses revealed a significant increase (CHT1,
p0.05; ChAT, p0.05) in protein expression in allografts on both day 9 and day 42 
compared with isografts at the same time-points after transplantation (Figure 4.10).  
 
4.6 Expression of CHT1 and ChAT protein by graft blood monocytes 
Immunohistochemistry was performed on paraffin sections from the renal cortex of isografts
and allografts (n=4 each). The immunohistochemical staining with antisera to CHT1 (Figure
4.11) and ChAT (Figure 4.12) resulted in a strong labelling of almost all leukocytes present in
allograft veins. In blood vessels of isografts, the staining intensity for both proteins tended to
be weaker (Figure 4.11-4.12). In addition to intravascular mononuclear leukocytes, antibodies 
to CHT1 and ChAT also stained endothelia, VSMC, components of the renal parenchyma, and
leukocytes infiltrating allografts (Figure 4.11-4.12). To prove that most blood cells 
immunopositive for CHT1 and ChAT are monocytes, double-staining experiments with the 
antibody ED1 directed to a CD68-like antigen expressed by monocytes/macrophages  [48]
were performed (Figure 4.11-4.12). The specificity of the staining was verified by adding
excess amounts of the specific peptides to the primary antibody solution, which dramatically
reduced the staining intensity (Figure 4.11-4.12). Series of controls omitting primary or 
secondary antibodies were performed (Figure 4.13). They clearly show lack of unspecific
straining in both single- and double-staining. 
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Figure 4.10: Detection of CHT1 and  ChAT on immunoblots of protein extracts from 
mononuclear leukocytes isolated on day 9 (9) and day 42 (42) post-transplantation from the 
blood vessels of renal isografts (iso) and allografts (allo). To confirm equal loading, the blots
were stained with antibodies to rat GAPDH. For each antibody used, one representative blot
out of two is shown. The specificity of the antisera was verified by adding excess amounts of
specific peptide (P) to the primary antibodies on a blot of leukocytes isolated from renal day 9
allografts. Blots were analysed densitometrically and the values obtained for CHT1 and ChAT 
were divided by the values for GAPDH. The mean of the data of day 9 isograft samples was 
set to one and all other values were calculated accordingly. Box plots show median and
percentiles 0, 25, 75 and 100; the circle indicates a value below 3 x standard deviation. 
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Figure 4.11: Immunohistochemical detection of CHT1 on paraffin sections of the cortex of 
isogeneic (iso) and allogeneic (allo) renal transplants on days 9 and 42 after transplantation.
All sections contain veins with few intravascular leukocytes in isografts and leukocyte
accumulations in allografts. CHT1 was labelled in brown with a peroxidase-coupled detection 
system, and the sections were slightly counterstained with hemalum. The specificity of the
antibody-binding was tested by adding excess amounts of the peptide used to raise the
antiserum (insert in allograft day 9), which attenuated the staining intensity. Double-staining 
experiments using mAb ED1 directed to a CD68-like antigen indicated that monocytes exhibit 
CHT1 immunoreactivity. ED1 is stained in red, bound antibodies to CHT1 are stained in blue
using an alkaline phosphatase-coupled detection system. The arrows are pointing to double-
positive monocytes and the arrow-heads point to CHT1-immunoreactive cells negative for the 
CD68-like antigen.  
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Figure 4.12: Immunohistochemical detection of ChAT on paraffin sections of the cortex of 
isogeneic (iso) and allogeneic (allo) renal transplants on days 9 and 42 after transplantation.
All sections contain veins with few intravascular leukocytes in isografts and leukocyte
accumulations in allografts. ChAT was labelled in brown with a peroxidase-coupled detection 
system, and the sections were slightly counterstained with hemalum. The specificity of the
antibody-binding was tested by adding excess amounts of the peptide used to raise the
antiserum (insert in allograft day 9), which attenuated the staining intensity. Double-staining 
experiments using mAb ED1 directed to a CD68-like antigen indicated that most cells 
immunopositive for ChAT are monocytes. ED1 is stained in red, bound antibodies to ChAT
are stained in blue using an alkaline phosphatase-coupled detection system. The arrows are 
pointing to double-positive monocytes and the arrow-heads point to ChAT-immunoreactive 
cells, negative for the CD68-like antigen.  
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Figure 4.13: Controls for immunohistochemical detection of CHT1 and ChAT on paraffin 
sections: A. single-staining omitting the primary antibody; B. double-staining omitting both 
primary antibodies; C. double-staining omitting antibody for ED1 - only blue staining for 
CHT1/ChAT is present; D. double-staining omitting antibodies to CHT1/ChAT - only red 
staining for ED1 is present. The substrate for alkaline phosphatase results in a yellow to
brownish unspecific back-ground, which is particularly strong in erythrocytes (B-D). 
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4.7 ACh concentration in graft blood leukocytes 
To confirm ACh production, mononuclear graft leukocytes were extracted and analysed by
HPLC. This experiment was performed by Prof. Dr. Ignaz Wessler from Department of 
Pathology, University of Mainz [143]. The chemical identity of ACh was corroborated by the 
use of standards and by specific degradation by ACh-esterase coupled to an HPLC column.
ACh is present in all leukocyte samples isolated from grafts, but not in leukocytes from
healthy control kidneys (Figure 4.14). The ACh content per million cells did not differ among 
leukocytes isolated from isografts and allografts, however, there is a significant (p0.05) 
increase in ACh concentration in leukocytes from day 42 isografts compared with leukocytes
from healthy control kidneys (Figure 4.14). 
 
 
Figure 4.14: ACh concentration in intravascular leukocytes isolated from healthy control 
kidneys (C), isografts (iso) and allografts (allo) on days 9 (9) and 42 (42) after transplantation.
ACh was analysed by HPLC combined with electrochemical detection. The box plots show 
median and percentiles 0, 25, 75 and 100. ACh measurements was performed by I. Wessler, 
Mainz. 
 
4.8 VAChT, OCT1, OCT2 and OCT3 mRNA-expression by graft blood leukocytes  
The mRNA-expression of VAChT, OCT1, OCT2 and OCT3 was analysed by real time RT-
PCR in mononuclear leukocytes isolated from renal F344 to LEW allografts, isografts and
healthy control kidneys. No VAChT mRNA-expression was detected. Intravascular 
leukocytes of all groups express OCT1, OCT2 and OCT3 mRNA (Figure 4.15). Only OCT1 
and OCT2 mRNA-expression in day 9 allografts decreased significantly (OCT1, p0.05; 
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OCT2, p0.05) compared to isografts (Figure 4.15, A-B). OCT1 and OCT2 mRNA-
expression in intravascular leukocytes from day 42 isografts and allografts remains on the
control levels (Figure 4.15, A-B). OCT3 mRNA level does not differ between the  groups of 
interest (Figure 4.15, C). The melting curves of the products (OCT1, OCT2, OCT3) indicated
homogeneity and electrophoresis revealed a single band with the expected molecular weight
of 150 bp for OCT1, 160 bp for OCT2, and 153 bp for OCT3. DNA sequencing confirmed the 
specificity of the PCRs. In negative controls, no product was obtained. 
 
4.9 Rivastigmine-treatment of renal allograft recipients 
As a proof of principle that endogenous ACh can contribute to CAV, renal allograft recipients
were treated with rivastigmine, the dual-specific AChE and BChE inhibitor (n=5) or placebo
(n=5). Six months after transplantation, both renal allograft groups, placebo and rivastigmine-
treated animals, exhibit typical hallmarks of CAI like vascular remodelling, glomerular 
damage, patchy fibrosis, leukocyte infiltration or TA. The arterial thickness, including media
and intima, as well as the percentage of the arteries exhibiting intimal hyperplasia is
significantly (p0.05) increased in placebo-treated allograft recipients compared with healthy 
control kidneys (Figure 4.16 A-B). However, clear significant (p0.05) differences can be 
observed between rivastigmine- and placebo-treated animals (Figure 4.16, A-B). In 
rivastigmine-treated recipients, the proportion of arteries exhibiting intimal hyperplasia and
the thickness of the arterial wall, including media and intima are increased (Figure 4.16, A-D). 
To exclude the possibility that rivastigmine-treatment results in arterial remodelling in other 
organs, arteries of recipient lungs and spleens were investigated (Figure 4.17). No differences
were seen between rivastigmine and placebo-treated animals. Only lung arteries from graft 
recipients treated with placebo were slightly thicker compared to controls (Figure 4.17, A). To
investigate graft function, creatinine clearance and proteinuria were measured monthly.
During six months, renal function gradually decreased, however, there are no significant
differences between placebo- and rivastigmine-treated recipients (Figure 4.18, A-B). 
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Figure 4.15: Quantitative RT-PCR analyses of (A.) OCT1, (B.) OCT2 and (C.) OCT3
mRNA-expression in intravascular leukocytes isolated from healthy control kidneys (C), 
renal isografts (iso) and allografts (allo) on days 9 (9) and 42 (42) after transplantation. Data
are expressed as arbitrary units which are normalised to one unit in controls. The box plots
indicate median and percentiles 0, 25, 75 and 100; circles indicate data beyond 3 x standard 
deviation. 
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Figure 4.16: Vascular remodelling in renal allografts 6 months after transplantation
from recipients treated with placebo or the cholinesterase inhibitor rivastigmine.
Histological sections were stained with acidic Orcein to visualise the internal (arrow) and 
external (arrow-head) elastic lamina of arteries of the muscular type (C,D). A. To measure the 
relative arterial thickness, the inner diameter of arterial structures surrounded by the external
elastic lamina, including T. media, T. intima and lumen was divided by the diameter of the
vascular lumen. B. The percentage of graft arteries with intimal hyperplasia was determined.
C-D. Sections of kidneys are shown depicting an example of a normal artery (control, C.) and 
D. an example of a severely remodelled artery (rivastigmine). The box plots show median and
percentiles 0, 25, 75 and 100; the circle indicates a value below 3 x standard deviation. 
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Figure 4.17: Systemic effects of rivastigmine-treatment. The vascular morphology was 
investigated in lungs (A, C) and spleens (B, D) of allograft recipients. Normal healthy organs 
from untreated rats were included as additional controls. A-B. To measure the relative arterial 
thickness, the inner diameter of arterial structures surrounded by the external elastic lamina, 
including T. media, T. intima and lumen was divided by the diameter of the vascular lumen.
C-D. The percentage of graft arteries with intimal hyperplasia was determined. The box plots
show median and percentiles 0, 25, 75 and 100; circles indicate data beyond 3 x standard 
deviation. 
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Figure 4.18: Graft function. A. Creatinine clearance and B. total urine protein were 
determined monthly for placebo- and rivastigmine-treated animals. The box plots show 
median and percentiles 0, 25, 75 and 100; circles indicate data beyond 3 x standard deviation.
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5. Discussion 
 
5.1 Experimental renal transplantation 
Renal transplantation in the F344 to LEW rat strain combination is an established model for 
human CAI. It has been first described in 1969 by White et al. [44], followed by Mahabir et 
al. [144] one year later. Allografts pass through an acute rejection episode, which is in most 
studies suppressed with the calcineurin inhibitor CsA for 10 days after transplantation. In the 
long-run, allografts develop CAN, which is characterised by progressive proteinuria and renal
dysfunction caused by histopathological lesions like glomerulosclerosis, IF/TA, mononuclear 
cell infiltration, and vascular remodelling [42, 145]. Numerous immunological and non-
immunological factors contribute to the development of CAI. Treatment with CsA has been 
reported to be an important non-immunological cause [146]. 
CsA was first used in patients after renal transplantation and was immediately reported to
have nephrotoxic properties when used at the dose based on previous animal experiments
[147]. Thereafter, a lower dose of CsA was used in clinical studies, which effectively
diminished the risk of acute allograft rejection [148]. Acute CsA nephrotoxicity caused
functional changes in renal grafts, such as impaired tubular function, proteinuria, and reduced 
glomerular filtration rate. These changes were reported to be reversible after termination of 
the treatment [148-150]. In 1984, Myers et al. [151] investigated the long-term effects of CsA:
the expected reversible decrease in glomerular filtration rate, irreversible progressive 
glomerulosclerosis and tubulointerstitial injury [151]. Later on, the chronic nephrotoxicity of 
CsA was confirmed [152-153]. Conflicting results were obtained in experimental kidney
transplantation. In renal DA to LEW allografts, even high CsA doses did not provoke any 
histopathological or biochemical changes [154]. In contrast, in LEW recipients of F344 renal 
allografts, CsA was nephrotoxic [155].  
In this project, renal transplantation was performed in the F344 to LEW rat strain 
combination, however, no immunosuppression was used to avoid nephrotoxicity induced by
CsA. After transplantation and reversible acute rejection, allografts are spontaneously
accepted. In the long-run, CAI develops with all characteristic histopathological lesions and
progressive loss of function [156]. Depending on the severity of the ischemia/reperfusion
injury and on the reduction of renal mass, CAI can also be seen in renal isografts [156-158].
Similar results of renal transplantation in F344 to LEW rat strain combination without CsA-
treatment have been published [47, 159-161]. There are clear advantages in investigating the 
development of CAI in an animal model in the absence of immunosuppression. There is no 
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interference with acute rejection, which is an important risk factor for the development of
CAN [7-9], thus, it enables to investigate factors triggering CAAN during acute rejection 
episodes. These factors could be promising targets for new therapeutic approaches preventing 
CAN. Furthermore, CAN can be investigated in the absence of potentially  confounding 
nephrotoxic effects of CsA.  
 
5.2 Leukocyte accumulation 
 
In previous studies, our laboratory demonstrated that during fatal and reversible acute
rejection, stunning amounts of mononuclear leukocytes accumulate in all parts of the vascular
bed of the graft including arteries [47, 49]. Interestingly, the number of leukocytes present in 
the blood vessels of isograft recipients on days 4 [49], 9 [47], and 42 after transplantation is 
doubled throughout in comparison to untreated control kidneys. It is unknown if this is due to 
ischemia/reperfusion injury, to renal denervation or to hyperperfusion in the absence of a
contralateral kidney. Pilot experiments on the time course of intravascular leukocyte
accumulations in the F344 to LEW model already suggested that after reversion of acute
rejection, the number of intravascular leukocytes remains at an elevated level [156]. Here, 
these preliminary data are corroborated. Six weeks after transplantation, the cell number in 
allografts increase about 3-fold compared to isografts, thus, the accumulation of intravascular
leukocytes in the vascular bed of allografts is a long-lasting process. 
 
5.3 Thickness of arterial wall during reversible acute rejection  
 
On day 9 after allogeneic but not isogeneic transplantation, a transient increase of the relative 
thickness of the arterial wall including media, intima and adventitia is observed. There is, 
however, virtually no intimal hyperplasia, and the internal elastic membrane is intact.
Previously, the adventitia was described as an element of the artery only having a supportive 
role. Strong evidence suggests that it actively participates in vasoconstriction and
vasorelaxation [162-163]. On day 9 after allogeneic transplantation, the adventitia is 
infiltrated by numerous leukocytes. These cells may induce adventitial fibrosis. Later on, the 
number of cells surrounding the artery decreases together with the thickness of adventitia. 
Several factors contribute to the regulation of the vasotonus, such as NO – a vasorelaxant, and 
endothelin (ET-1) – a vasoconstrictive mediator. Besides being a vasorelaxant, NO regulates 
leukocyte adhesion and proliferation of SMC. Both NO and ET-1 are produced by EC and 
inflammatory cells. Impaired regulation of the vasotonus can be related with EC dysfunction, 
which is frequently present after allogeneic transplantation [164]. It may be related to IR 
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injury or damage of EC by intravascular leukocytes accumulating during reversible acute 
rejection [164]. ET-1 is known to be upregulated shortly after transplantation in response to
IR injury [165]. Additionally, the adventitia has been shown to contract in response to ET-1,
contributing to vasoconstriction [163]. Thickening of media and intima observed on day 9
after allograft transplantation is probably at least in part caused by functional changes
resulting in contraction.  
 
5.4 CAN 
 
Within 6 months after transplantation, allograft recipients develop typical hallmarks of CAN.
Vascular remodelling, including intimal and medial hyperplasia and disruption or doubling of
the internal elastic membrane, is clearly visible in allograft arteries on day 182 after 
transplantation and increased compared with isografts. Even a small decrease in the arterial 
lumen caused by intimal thickening can impair renal perfusion due to the increase in the 
resistance of the blood flow [166]. Vascular remodelling and progressive fibrosis are not the 
only signs of CAI in renal allografts. Glomerular damage and TA are also present. Due to the 
changes in the renal tissue, the function of renal allografts is decreased compared with
isografts [156]. 
 
5.5 ACh synthesis 
 
I sought to analyse the expression of essential elements of the machinery for ACh synthesis, 
CHT1, ChAT and CarAT in intravascular leukocytes from renal isografts, allografts and 
healthy control kidneys. The results of the real-time RT-PCR show that CHT1 expression is 
upregulated. Unexpectedly, leukocytes from healthy control kidneys expressed higher 
amounts of CHT1 mRNA compared to isografts, which is in contrast to our HPLC
experiments, where no ACh was detected in control leukocytes. In contrast to CHT1, ChAT 
mRNA was not detectable in some samples. Previously, ChAT mRNA was detected by the 
highly sensitive nested RT-PCR in leukocytes from the blood vessels of renal allografts
undergoing fatal acute rejection [48]. As it was possible to detect small amounts of ChAT
mRNA in few samples (data not shown), I assume that low levels of ChAT mRNA are also 
expressed by the leukocytes in other groups.  
In addition to ChAT mRNA, CarAT mRNA-expression was investigated in intravascular 
leukocytes. CarAT has been reported to be an effective enzyme for ACh synthesis in the 
absence of ChAT [113, 167]. Intravascular leukocytes from all experimental groups are 
expressing CarAT mRNA and its level is increased in allografts on day 42 compared with all
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other groups. This result is in line with the CHT1 mRNA-expression levels, which are also 
increased in allograft leukocytes and suggest that intravascular leukocytes produce higher 
amounts of ACh on day 42 after allogeneic transplantation. The results clearly show that 
intravascular leukocytes express the mRNA of enzymes necessary for ACh synthesis and that
the mRNA-expression is increased after allograft transplantation.  
On the protein level, CHT1 and ChAT were detected in intravascular allograft leukocytes both 
by immunoblotting and by immunohistochemistry, also suggesting that intravascular 
leukocytes including monocytes can produce ACh. In line with our hypothesis, both proteins
were expressed at higher levels in allografts.  
In addition to intravascular leukocytes, mRNA-expression of CHT1 and ChAT was analysed 
in homogenates of the renal tissue. CHT1 and ChAT mRNA is detected in the kidney of
animals from all experimental groups, but there is no significant increase in mRNA-
expression in allografts. Unexpectedly, there is a significant decrease in CHT1 mRNA-
expression in kidneys of allograft recipients on day 42. As CHT1 is produced by endothelial
cells, VSMC and elements of renal parenchyma [48, 125-126], damage of renal tissue due to 
progression of allograft rejection could be the cause of reduced CHT1 expression. However,
no such effect was visible for ChAT, which is also produced by these cells. The tissue protein 
expression of ChAT and CHT1 was not investigated by Western blotting because this study 
focused on intravascular cells. There is, however, no drastic decrease in the intensity of 
immunohistochemical staining with antibodies to CHT1 and ChAT on sections from allografts
on day 42 compared with other groups.  
Recently, a new member of choline transporter family has been investigated, choline
transporter-like protein (CTL-1) and has been shown to be an efficient choline transporter in 
rat tubular epithelial cells in the absence of CHT1 [168]. In this study, CTL-1 expression was 
not investigated, which may be of interest in further studies.   
 
5.6 Leukocytic ACh content 
 
ACh is a well-known neurotransmitter in vertebrates and invertebrates. It is also present in 
invertebrates without a nervous system such as sponges, where it acts as a local mediator 
[169]. ACh is also present in plants, fungi and in bacteria, where it plays different roles, such 
as the regulation of differentiation and communication [169-170]. These data show that ACh 
is present ubiquitously throughout the evolution and that it may regulate physiological 
functions as a local mediator as well as a neurotransmitter.  
The detection of leukocytic ACh in intravascular leukocytes, which was evidenced by HPLC, 
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just indicates that ACh is produced. By this method it is, however, not possible to indicate
how many ACh is actually released by intravascular graft leukocytes in vivo. Due to the 
ubiquitous expression of ACh-esterases, a reliable measurement of ACh in bodily fluids is
difficult. From functional analyses in vitro, however, it is known that monocytes from 
allografts undergoing fatal acute rejection but not cells from isografts release ACh, which 
binds to their AChR in an autocrine or paracrine fashion [48]. As intravascular leukocytes and 
allograft endothelia are in direct contact to each other and allograft blood vessels are almost
obstructed by leukocytes [47, 156], the velocity of the blood stream is likely to be severely
impaired in allografts. Hence, we conclude that ACh released by intravascular allograft
leukocytes may be locally active and bind to AChR expressed by endothelial cells.  
 
5.7 ACh release 
 
After proving that intravascular leukocytes produce ACh, molecules involved in the release of 
ACh were investigated. No VAChT mRNA- was detected in intravascular leukocytes (data 
not shown). In 2001, Wessler et al. [171-172] showed evidence that in the absence of VAChT, 
ACh can be released via OCT1 and OCT3 in the human placenta. In Xenopus oocytes, the 
release of ACh is mediated by OCT1 and OCT2 but not by OCT3 [173]. Similar results were 
shown for airway epithelial cells and urothelium [92, 113]. Additionally, OCT2 has been 
shown to partake in ACh transport in both directions (uptake and release) [174]. There is also 
evidence that the level of ACh in tracheal epithelial cells is increased in OCT1/2 double-
knockout mice, due to impaired ACh release [133]. Basing on these results, mRNA-
expression of all three types of OCTs was investigated. Intravascular leukocytes from all
experimental groups express OCT1, OCT2 and OCT3 mRNA. According to the publications 
of Lips et al. [92, 113] it can be expected that OCT1 and OCT2 represent a major release 
system for ACh in intravascular leukocytes. The mRNA-expression level of these two 
transporters decreases upon inflammation, starting in allografts on day 9, but not in isografts 
and remains on a low level until day 42 in both isografts and allografts. The OCT3 mRNA-
expression remains on similar levels in all groups of interest. Similar down-regulation of 
OCT1 and OCT2 but not of OCT3 has been shown by Lips et al. [175] in rat and mouse 
models of acute allergic airway inflammation. Although the expression of the OCTs in
intravascular leukocytes was not confirmed on protein level, mRNA-expression data suggest
that the release of ACh from intravascular graft leukocytes might be impaired in allografts
during chronic renal rejection. Combined with the increased expression of CHT1 mRNA and 
CHT1 and ChAT proteins in both allograft groups, an increased level of ACh in intravascular 
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leukocytes isolated from allografts can be expected. However, the ACh levels are similar in 
intravascular leukocytes from allografts, isografts and from healthy control kidneys, which
suggests the presence of additional ACh release mechanisms. Schlereth et al. [176] has shown
that the release of ACh from human skin does not fully depend on OCTs.  
 
5.8 ACh and CAV 
 
To prove that endogenous ACh can promote CAV, allograft recipients were treated with 
rivastigmine, a dual-specific AChE and BChE inhibitor. The inhibition of ACh degradation
results in increased endogenous levels of ACh. Treatment with rivastigmine started three 
weeks after transplantation, to avoid a possible inhibition of the acute rejection episode by 
increased ACh levels. A strong antiinflammatory effect of ACh on cells of the innate immune 
system has been documented before [177]. nAChRs are expressed by variety of leukocytes
and other cytokine-producing cells [53] and ACh has been shown to decrease production of 
TNF-α, IL-1, IL-6 and IL-18 by macrophages, but not antiinflammatory IL-10 via -7 
nicotinic receptors [178]. Additionally, -7 subunit deficient mice are more susceptible to 
inflammatory stimuli such as lipopolysaccharide, and have higher serum levels of 
proinflammatory cytokines during inflammation [179]. The dose of rivastigmine, which was 
administered to the allograft recipients, has been previously shown to be effective [180]. Six 
months after transplantation, renal allografts were analysed histomorphometrically. Vascular 
remodelling is more prominent in rivastigmine-treated recipients compared with placebo-
treated animals of healthy control kidneys. This holds true for all layers of the arterial wall 
including T. intima, T. media and T. adventitia. In addition to increased ACh levels, AChE 
inhibitors have been shown to interact with -7 nicotinic receptors, and increase their 
expression [181].  
In addition to increased ACh levels in the blood vessels of allografts, systemic treatment with
rivastigmine probably also results in increased ACh levels in other parts of the body, which
may induce a generalised vascular remodelling. To exclude that possibility, arteries in lungs 
and spleens were investigated and no significant differences between placebo and 
rivastigmine-treated recipients were found. These results highlight the importance of ACh 
locally released by intravascular allograft leukocytes. There is, however, a significant 
difference in the thickness of the lung arteries in placebo-treated animals compared with 
control animals. This could be due to animal ageing, as treated animals are 6 months older 
than control animals or to vascular remodelling caused by thrombi [166, 182], which may 
form after transplantation. It has been previously shown that thrombi may be involved in 
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forming neointimal hyperplasia [183]. Thrombi also have the properties to induce the
accumulation of inflammatory cells and increase the release of proinflammatory cytokines 
[184]. 
Apart from intravascular graft leukocytes, other sources of ACh may contribute to vascular
remodellling in allografts: endothelial cells, smooth muscle cells, infiltrating graft leukocytes,
which all are immunopositive for ChAT and CHT1 in our immunohistochemical staining and
have been described to produce ACH [185]. Another possible source of local ACh release -
local neurons - can be excluded, because nerves are cut during transplantation. 
On the basis of our data is tempting to propose the following steps in the pathogenesis of
CAV: mononuclear leukocytes accumulate in close contact to allograft endothelial cells. 
These intravascular leukocytes are activated to produce ACh, which is released and acts in a
paracrine fashion on nAChR expressed by allograft endothelia. In response to leukocytic ACh, 
endothelial cells proliferate and produce growth factors such as VEGF [186], which in turn 
mobilises VSMC from the media and promotes their proliferation. Smooth muscle cells may 
also be directly attracted by leukocytic ACh [186]. Both endothelial and smooth muscle cells 
contribute to the formation of intimal hyperplasia typical for CAV [166]. Similar processes 
may also happen in isografts. In isografts investigated in this study, presumably less ACh is
released, which is quickly flushed away by the blood stream, because of the significantly
lower number of leukocytes present in isografts.  
 
5.9 Conclusions 
In conclusion, our study demonstrates that leukocytes accumulating in the blood vessels of
renal allografts undergoing chronic rejection produce ACh and that endogenous ACh
contributes to the pathogenesis of CAV. Pharmacological targeting of vascular AChRs seems
to be a promising strategy to prevent or cure chronic renal allograft rejection. 
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6. Summary 
 
Leukocytes, which accumulate in graft blood vessels during fatal acute rejection of 
experimental renal allografts, synthesise and release acetylcholine (ACh). In this study, I 
tested the hypothesis that ACh produced by leukocytes accumulating in graft blood vessels
contributes to the pathogenesis of chronic renal allograft vasculopathy (CAV). 
Kidneys were transplanted in the allogeneic Fischer 344 to Lewis rat strain combination.
Isogeneic transplantations were performed in Lewis rats. Intravascular graft leukocytes were 
investigated during an acute rejection episode on day 9 post-transplantation and during the 
process of vascular remodelling on day 42. The expression of essential elements for ACh
synthesis and release was analysed by quantitative RT-PCR, Western blotting and
immunohistochemistry. Furthermore, renal allograft recipients were treated with rivastigmine, 
an ACh-esterase inhibitor, or placebo. 
Nine days after transplantation, numerous leukocytes accumulated in the blood vessels of the
allograft (allograft: ~140 x 106; isograft: ~10 x 106). Leukocyte numbers decreased until day 
42 after allogeneic transplantation (allograft: ~40 x 106; isograft: ~10 x 106). Within 6 months 
after transplantation, allografts developed typical hallmarks of chronic allograft injury -
vascular remodelling, fibrosis, glomerular damage, tubular atrophy, and decreased renal
function. The mRNA and protein expression of the high-affinity choline transporter was 
upregulated in allograft leukocytes on day 9 and day 42. Choline acetyltransferase (ChAT)
mRNA was detected only sporadically. However, increased amounts of ChAT protein were
detected in intravascular leukocytes from day 9 and 42 allografts compared with isografts.
Carnitine acetyltransferase mRNA expression was increased in intravascular leukocytes from 
day 42 allografts compared with other groups. ACh itself was present at about the same level 
in leukocytes from isografts and allografts but absent in leukocytes from untreated kidneys. 
No vesicular acetylcholine transporter mRNA was detected but the mRNA of polyspecific 
organic cation transporters 1, 2, and 3 was present in all samples. In line with the hypothesis
that endogenous ACh contributed to the pathogenesis of CAV, rivastigmine-treatment 
enhanced the severity of experimental CAV. 
In conclusion, the results are in line with the hypothesis that leukocytic ACh contributes to the 
pathogenesis of CAV. The non-neuronal cholinergic system seems to be a promising target for
the development of novel therapeutic approaches preventing CAV. 
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7. Zusammenfassung 
 
Leukozyten, die sich während der akuten fatalen Abstoßung in den Blutgefäßen
experimenteller Nierentransplantate ansammeln, produzieren Acetylcholin (ACh). In dieser
Studie überprüfte ich die Hypothese, dass leukozytäres ACh zur Pathogenese der chronischen 
Transplantatvaskulopathie (CAV) beiträgt. 
Nieren wurden in der allogenen Fischer 344 auf Lewis Rattenstammkombination
transplantiert. Isogene Transplantate erfolgten in der Lewis-Ratte. Intravasale Transplantat-
leukozyten wurden während einer akuten Abstoßungsepisode am 9. postoperativen Tag
untersucht sowie während des Gefäßumbaus am Tag 42. Die Expression wesentlicher
Elemente der ACh-Synthese und -Freisetzung wurde durch quantitative PCR, Western
blotting und Immunhistochemie untersucht. Weiterhin wurden Empfänger allogener
Transplantate mit Rivastigmin, einem ACH-Esteraseinhibitor oder mit Placebo behandelt. 
Bis zum 9. postoperativen Tag sammelten sich zahlreiche Leukozyten in den Blutgefäßen der 
Transplantate an (allogenes Transplantat: ~140 x 106; isogenes Transplantat: ~10 x 106). Bis 
zum Tag 42 sanken die Leukozytenzahlen wieder, blieben jedoch im Vergleich zu
entsprechenden isogenen Transplantaten vierfach erhöht (allogenes Transplantat: ~40 x 106; 
isogenes Transplantat: ~10 x 106). Innerhalb von 6 Monaten entwickelten die Transplantate
typische Anzeichen der chronischen Transplantatschädigung – Gefäßumbau, Fibrose, 
Glomerulopathie, Tubulusatrophie und Funktionsstörung. An den Tagen 9 und 42 war die
mRNA- und Proteinexpression des hochaffinen Cholintransporters hochreguliert. Die mRNA
der Cholinacetyltransferase (ChAT) ließ sich nur sporadisch nachweisen. Hingegen war in
Leukozyten aus allogenen Nierentransplantaten (Tag 9 und Tag 42) die Menge des ChAT-
Proteins im Vergleich zu isogenen Transplantaten erhöht. Im Vergleich zu allen anderen
Gruppen war die Expression der Carnitinacetyltransferase am Tag 42 nach allogener
Transplantation erhöht. ACh selbst war etwa in gleicher Menge in Leukozyten aus isogenen
und allogenen Transplantaten nachweisbar, jedoch nicht in Leukozyten aus unbehandelten
Nieren. Die mRNA des vesikulären Acetylcholintransporters war nicht messbar, wohl aber die
mRNA der organischen Cationentransporter-1, -2 und -3. In Übereinstimmung mit der 
Hypothese dass endogenes ACh zur Pathogenese der CAV beiträgt, verschlimmerte die
Behandlung mit Rivastigmin den Schweregrad der CAV. 
Die Ergebnisse sind folglich mit der Hypothese vereinbar, dass leukozytäres ACh zur
Pathogenese der CAV beiträgt. Das non-neuronale cholinerge System scheint ein 
vielversprechender Ansatzpunkt zur Entwicklung neuer Therapien der CAV zu sein. 
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